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Abstract (word count 153) 154 
 155 
Pulmonary hypertension is highly heterogeneous and despite treatment 156 
advances it remains a life shortening condition. There have been 157 
significant advances in imaging technologies, but despite evidence of their 158 
potential clinical utility practice remains variable, dependent in part on 159 
imaging availability and expertise. This statement summarises current and 160 
emerging imaging modalities and their potential role in the diagnosis and 161 
assessment of suspected pulmonary hypertension. It also includes a 162 
review of commonly encountered clinical and radiological scenarios, and 163 
imaging and modeling-based biomarkers. An expert panel was formed 164 
including clinicians, radiologists, imaging scientists and computational 165 
modelers. Section editors generated a series of summary statements 166 
based on a review of the literature and professional experience and 167 
following consensus review, a diagnostic algorithm and fifty five 168 
statements were agreed. The diagnostic algorithm and summary 169 
statements, emphasise the key role and added value of imaging in the 170 
diagnosis and assessment of pulmonary hypertension and highlight areas 171 
requiring further research.  172 
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Introduction 173 
 174 
Pulmonary Hypertension (PH) is highly heterogeneous, is challenging to 175 
diagnose and treat and has a survival worse than many forms of common 176 
cancer [1, 2]. It ranges from a rare form, pulmonary arterial hypertension 177 
(PAH) characterised by a vasculopathy and frequently severe elevation of 178 
pressure, to more common usually mild elevations of pulmonary artery 179 
pressure seen in severe cardiac and respiratory disease [3, 4]. The current 180 
system of classification identifies 5 groups, each with distinct 181 
pathophysiological characteristics [2, 3, 5]. The diagnosis of pulmonary 182 
hypertension is usually first suggested by echocardiography or chest 183 
radiography with confirmation of an elevated pulmonary artery pressure at 184 
right heart catheterization. Phenotyping is based on a careful history, 185 
blood testing for associated conditions, detailed physiological and imaging 186 
investigations. 187 
 188 
The treatment of pulmonary hypertension is dependent on the underlying 189 
cause. For patients with PAH, drug therapy targeting imbalances in 190 
vasoconstrictor and vasodilator mediators, have been shown to improve 191 
exercise capacity, quality of life and event free survival [6-13]. However, 192 
PAH remains a life limiting and debilitating condition. In chronic 193 
thromboembolic pulmonary hypertension (CTEPH) pulmonary 194 
endarterectomy is an established technique with excellent long-term 195 
outcomes [14-18] and more recently drug therapy [19-21] and balloon 196 
pulmonary angioplasty [22, 23] have shown benefit in selected groups of 197 
patients with CTEPH. For patients with other forms of pulmonary 198 
hypertension, such as in association with cardiac and respiratory disease, 199 
trials of PAH therapies have thus far been disappointing [24-26]. Accurate 200 
classification is key not only as it defines treatment but also prognosis [27-201 
29] and careful assessment is therefore crucial in the assessment of 202 
patients with suspected pulmonary hypertension. 203 
 204 
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Current assessment tools in the pulmonary hypertension clinic and end-205 
points used in clinical trials may be limited by a number of factors. These 206 
include insensitivity to change, lack of repeatability and the invasive nature 207 
of tests. There is a need to identify new tools and end-points to aid the 208 
physician both in the clinical environment and in studies of new 209 
interventions [30-36]. Importantly over the last 20 years there has been 210 
major advances in imaging techniques and their application including the 211 
use of echocardiography, nuclear medicine, CT scanning, MRI and 212 
molecular imaging. There is growing evidence demonstrating the value of 213 
various imaging modalities in the classification, risk stratification, and 214 
follow-up of patients with pulmonary hypertension. Imaging studies have 215 
also provided insights into pathophysiological mechanisms [37-45].  216 
 217 
The use of imaging varies across the globe due to a variety of factors 218 
including personal preference, availability and cost. Given the complex 219 
nature of certain imaging investigations there are also differences in 220 
methods of scan acquisition and post-processing within a given modality.  221 
Consequently, the PVRI have identified imaging as an important area for 222 
international collaboration, with the aim of developing evidence based 223 
statements and sharing best practice, whilst recognizing that approaches 224 
need to be tailored to imaging availability. This statement on imaging in 225 
pulmonary hypertension is aimed at physicians (including cardiologists and 226 
pulmonologists), pulmonary hypertension specialists, radiologists and 227 
imaging scientists.   228 
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Methods 229 
 230 
The PVRI Imaging Task force met for the first time in Rome in 2016 with 231 
an aim to improve imaging practice globally in pulmonary hypertension.  A 232 
summary statement from the PVRI was identified as an important first step 233 
in achieving this goal. Participants were invited from the existing PVRI 234 
membership in addition to international imaging experts. The group 235 
included representatives from wide ranging professional backgrounds and 236 
different geographical areas with varied access to imaging.  237 
 238 
Groups of authors were assigned to specific sections to review current 239 
literature, identify summary statements and develop a diagnostic 240 
algorithm.  An editorial board met to preview and refine summary 241 
statements and ensure uniformity of style (DGK, DL, JVC, AJS).  To be 242 
included in the final document, summary statements required agreement 243 
of 80% of authors. Statements not meeting this requirement were 244 
reworded until this threshold was reached or the statement rejected. Given 245 
the rapid development of imaging technologies, the recommendations 246 
reflect a combination of published evidence, current practice, and expert 247 
opinion.  248 
 249 
All authors read and approved the manuscript prior to submission. 250 
  251 
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Section 1: Imaging modalities used in the assessment of 252 
pulmonary hypertension 253 
 254 
Chest radiography  255 
 256 
Summary Statements 257 
A chest radiograph is recommended as the initial imaging test in the 258 
assessment of unexplained breathlessness.  259 
A normal chest radiograph does not exclude the diagnosis of pulmonary 260 
hypertension 261 
Features of pulmonary hypertension include pulmonary artery enlargement 262 
and cardiomegaly. 263 
 264 
Chest radiography 265 
Patients with pulmonary hypertension frequently present with 266 
breathlessness. The principal role of the chest radiograph (CXR) is to 267 
identify other common causes of breathlessness (e.g. parenchymal lung 268 
disease, pneumonia, pulmonary oedema, pleural effusion, and 269 
pneumothorax). The findings of pulmonary hypertension on CXR vary. 270 
There may be enlargement of the central pulmonary arteries with pruning 271 
of the peripheral vessels, features that were observed in the majority of 272 
patients in a registry of patients with idiopathic pulmonary hypertension 273 
[46]. In addition, cardiomegaly and features suggestive of right atrial 274 
enlargement may be observed. However, a normal CXR cannot exclude 275 
the diagnosis, and the CXR may be normal, where pulmonary artery 276 
pressure elevation is modest. Radiographic features may also suggest the 277 
cause of pulmonary hypertension, such as upper lobe venous diversion 278 
and left atrial enlargement in patients with left heart disease, vascular 279 
plethora and peripheral pruning in patients with Eisenmenger physiology, 280 
and interstitial opacities in patients with diffuse parenchymal lung disease. 281 
 282 
 283 
 284 
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1.2: Echocardiography  285 
 286 
Summary Statements  287 
Echocardiography is the test of choice in the initial evaluation of suspected 288 
pulmonary hypertension 289 
Echocardiography should include an assessment of pulmonary artery 290 
pressure, cardiac and valvular function  291 
A probability of pulmonary hypertension should be generated using 292 
estimated pulmonary artery pressure and additional echocardiographic 293 
features  294 
Doppler and 2D echocardiography remains the screening test of choice in 295 
the evaluation of suspected pulmonary hypertension [47-50].  Whilst right 296 
ventricular systolic pressure from the continuous wave Doppler of the peak 297 
tricuspid regurgitant velocity (TRV) is the most well-known tool for 298 
assessing the presence or absence of pulmonary hypertension, this metric 299 
can be subject to several limitations resulting in over or under estimation of 300 
the true pulmonary artery systolic pressure (PASP) [51].  Over the last 301 
decade, there have been many studies evaluating the role of clinically 302 
useful and readily available echo-Doppler parameters that allow one to 303 
move beyond the PASP and assess not just the likelihood of pulmonary 304 
hypertension, but also the hemodynamic underpinnings of the disease (ie. 305 
Left heart disease vs. PAH) [52, 53]. As noted in the most recent 306 
European Society of Cardiology (ESC)/European Respiratory Society 307 
(ERS) pulmonary hypertension guidelines, “echocardiography should 308 
always be performed when pulmonary hypertension is suspected and may 309 
be used to infer a diagnosis of pulmonary hypertension in patients in 310 
whom multiple different echocardiographic measurements are consistent 311 
with this diagnosis,” even in the absence of an elevated TRV [54]. This can 312 
then be used to generate a probability of pulmonary hypertension which 313 
will inform the diagnostic strategy and  “decide the need for cardiac 314 
catheterization in individual patients” [54].  Furthermore, several echo-315 
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Doppler parameters have been shown to have prognostic value in the 316 
setting of established pulmonary hypertension. 317 
 318 
Clinically useful measures of pulmonary hypertension (ie elevated right 319 
ventricular afterload) on echocardiography include characteristics of the 320 
RV outflow tract (RVOT) pulse wave Doppler envelope such as a reduced 321 
acceleration time (< 100 ms) [53, 55-57], systolic notching [53, 58, 59], 322 
and pulmonary insufficiency velocity to estimate mean pulmonary artery 323 
pressures, as well as interventricular septal flattening (as characterized by 324 
the eccentricity index) [60], increased right to left ventricular ratio (0.8–1.0, 325 
1.1–1.4, and ≥1.5 corresponding to mild, moderate and severe right 326 
ventricular dilatation, respectively) [52, 54], right ventricular hypertrophy 327 
and right atrial dilation [61] and measures of right ventricular function 328 
including tricuspid annular plane systolic excursion (TAPSE) [62, 63], and 329 
right ventricular fractional area change (RVFAC) [63-65].  While RVFAC is 330 
often limited in the setting of severe right ventricular enlargement [52, 63, 331 
66], TAPSE is a reproducible measure of right ventricular function which 332 
measures the total displacement of the heart from the right ventricular 333 
base toward the apex in systole, and correlates with radionuclide-derived 334 
right ventricular ejection fraction [63].  TAPSE has also been shown to be 335 
prognostic of poor outcome in pulmonary hypertension in all-comers [62], 336 
as well as in follow-up assessment in a PAH population after initiation of 337 
pulmonary hypertension therapy [67, 68].  However, TAPSE has not been 338 
shown as an effective marker of right ventricular function in pediatric PH 339 
[69].  Other echocardiographic measures include the myocardial 340 
performance (Tei) index [70] and S’ obtained from tissue Doppler imaging 341 
of the tricuspid annulus [71]. Markers of adverse outcomes include 342 
pericardial effusion and enlarged right atrium [72]. More recently, right 343 
ventricular longitudinal strain using 2D speckle tracking has been 344 
employed in the quantification of right ventricular function in patients with 345 
pulmonary hypertension, and has been shown to be impaired in patients 346 
with pulmonary hypertension, a predictor of mortality [73-76] and useful for 347 
assessment of therapy response [77, 78] .  Lastly, given the complex 348 
anatomy of the right ventricle, recent investigation has focused on the use 349 
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of 3D echocardiography [79] and strain to assess global and regional right 350 
ventricular structure and function and predict outcomes in pulmonary 351 
hypertension [80].  352 
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 14 
Nuclear medicine imaging  353 
 354 
Summary statements 355 
A normal perfusion SPECT (single photon emission computed 356 
tomography) excludes chronic thromboembolic disease that will benefit 357 
from pulmonary endarterectomy and balloon pulmonary angioplasty 358 
Ventilation and perfusion SPECT or SPECT CT is superior to planar 359 
scintigraphy 360 
In unexplained hypoxemia a nuclear medicine shunt assessment can be 361 
used to identify the presence of a right to left shunt 362 
In patients with suspected pulmonary artery sarcoma positron-emission 363 
tomography (PET) is recommended 364 
 365 
Ventilation/perfusion single photon emission tomography (V/Q SPECT) is 366 
recommended by the European Society of Cardiology (ESC) as the first 367 
line screening test for patients with chronic thromboembolic pulmonary 368 
hypertension (CTEPH) [1]. The technique is well established and has 369 
excellent diagnostic value particularly in the absence of lung disease.  The 370 
perfusion image involves exposure to ionizing radiation and requires 371 
injection of 99mTc labelled macroaggregated human albumin (10-372 
90microns in diameter) [20]. The macro-aggregated albumin becomes 373 
trapped within the small pulmonary arterioles, and a 3D image of 374 
pulmonary perfusion is acquired. In CTEPH typically peripheral wedge 375 
shaped defects of varying size are shown.  Mismatch to ventilation can be 376 
confirmed by comparing ventilation and perfusion images. The added 377 
value of performing ventilation imaging is debated and in many centres 378 
perfusion imaging alone is performed and compared to CT which better 379 
demonstrates parenchymal lung disease. CTEPH may be missed on CT 380 
as attenuated distal vessels, subsegmental stenosis and webs may not be 381 
appreciated. Early studies demonstrated that scintigraphy was more 382 
sensitive than CT for the detection of CTEPH. However, given advances in 383 
technology, more recent studies have shown that CT pulmonary 384 
angiography and CT SPECT techniques are equally sensitive [21–23]. 385 
Dual energy CT or CT with iodine mapping allow construction of relative 386 
DOI: 10.1177_2045894019841990 
 
 15 
perfusion maps in addition to providing angiographic images [81-87].  387 
Given that  99mTc labelled macroaggregates are trapped by small 388 
pulmonary arterioles, the presence of radioactive uptake in organs 389 
supplied by the systemic circulation (for example, the kidneys) can be 390 
used to identify the presence of a right to left shunt in hypoxemic patients 391 
with pulmonary hypertension [19]. 392 
 393 
Positron-emission tomography (PET) allows for observation of metabolic 394 
activity in the body which can be reconstructed to produce 3D images. 395 
Fluorodeoxyglucose (FDG), a glucose analogue, can be used to assess 396 
glucose uptake in tissues. PET scanning is commonly performed with 397 
simultaneous acquisition of CT and more recently with MRI for both 398 
functional and structural correlation [28]. In patients with suspected 399 
pulmonary artery sarcoma, PET will show high uptake allowing 400 
differentiation from chronic clot [29,30]. However, in acute clot FDG uptake 401 
may also be elevated, relative to unaffected vessels [88].  In PAH, uptake 402 
within the lungs and right ventricle have been demonstrated [24–27] 403 
although the clinical utility is uncertain. 404 
 405 
Computed tomography (CT) 406 
 407 
Summary Statements 408 
CT provides a non-invasive evaluation of vascular, cardiac, lung 409 
parenchymal, and mediastinal structures in patients with known or 410 
suspected pulmonary hypertension 411 
Significant parenchymal abnormalities may be seen on CT evaluation in 412 
the presence of normal spirometry, particularly when there is a significant 413 
reduction in gas transfer factor 414 
CT pulmonary angiography to assess the pulmonary vasculature should 415 
be considered in patients presenting with  pulmonary hypertension  416 
Imaging biomarkers from CT in patients suspected pulmonary 417 
hypertension should include measurement of pulmonary artery size, right 418 
to left ventricular ratio and left atrial size 419 
CT aids the classification of pulmonary hypertension  420 
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 421 
Computed tomography (CT) is increasingly recognized as a valuable 422 
imaging modality for the evaluation of known or suspected pulmonary 423 
hypertension. Advantages of CT include its widespread availability and 424 
accessibility, high spatial resolution, multi-planar imaging capabilities, and 425 
the ability to evaluate the pulmonary vasculature, lung parenchyma, 426 
cardiac, and mediastinal structures simultaneously. 427 
 428 
CT evaluation of vessels 429 
Pulmonary artery size can be easily measured and enlargement may 430 
suggest the diagnosis of pulmonary hypertension. Routine measurement 431 
is recommended particularly in patients at risk of pulmonary hypertension. 432 
For the diagnosis of pulmonary hypertension in lung disease a main 433 
pulmonary artery diameter greater than 29 mm had 84% sensitivity, 75% 434 
specificity, and 97% positive predictive value for pulmonary hypertension 435 
defined as a mean pulmonary artery pressure ≥ 25mmHg [89]. The 436 
reliability of measuring the main pulmonary artery (PA) diameter and the 437 
ratio of the PA to aorta (Ao) ratio, has also been studied in suspected 438 
pulmonary hypertension. Investigators found that a PA:Ao ratio > 1 was 439 
92% specific for a mPAP > 20mmHg  [90]. Other reports also support the 440 
use of pulmonary artery size in the clinical assessment of patients with 441 
pulmonary hypertension [91, 92]. However, it has been shown that an 442 
increase in pulmonary artery size also reflects disease duration and 443 
correlates only moderately with pulmonary arterial pressure [93]. It has 444 
previously been postulated that the presence of interstitial lung disease 445 
independently influences pulmonary arterial size [94], however, in a large 446 
cohort of patients with suspected pulmonary hypertension in association 447 
with interstitial lung disease, the presence and severity of interstitial lung 448 
disease did not influence pulmonary artery size which was found to be a 449 
useful diagnostic marker in patients with and without interstitial lung 450 
disease [95]. 451 
 452 
While contrast-enhanced CT angiography is the method of choice for the 453 
evaluation of suspected acute pulmonary embolism, its role in the 454 
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evaluation of the pulmonary vasculature in the setting of chronic 455 
thromboembolic pulmonary hypertension (CTEPH) has been a more 456 
recent development. Multiple findings are associated with CTEPH, 457 
including intravascular organising thrombi, webs, and regions of vascular 458 
narrowing or occlusion [96]. Mosaic perfusion of the lung parenchyma and 459 
enlarged bronchial arteries are also commonly seen [97-99]. 460 
 461 
Advanced CT capabilities have been studied in the evaluation of 462 
pulmonary hypertension. Dual-energy CT, provides an assessment of 463 
relative perfusion and improves the detection of peripheral vascular 464 
occlusion. In one study [85], dual energy CT showed 100% sensitivity on a 465 
per-patient basis compared to V/Q scintigraphy. However, there was 466 
imperfect agreement on a per-vessel basis. CT perfusion imaging may 467 
demonstrate residual perfusion abnormalities following therapy for acute 468 
pulmonary embolism, even in the absence of visualized thrombus on the 469 
angiographic portions of the study [100]. Perfusion imaging can also 470 
estimate cardiac output and in a small pilot study could detect pulmonary 471 
hypertension with high sensitivity and specificity [101, 102]. 472 
 473 
Pulmonary arterial hypertension is associated with vascular remodeling, 474 
including loss of arterial branching and increased vessel tortuosity. CT 475 
angiography can quantify these features, using fractal dimension and the 476 
ratio of actual vessel length to shortest linear distance to estimate 477 
tortuosity. Studies have shown these to correlate with hemodynamic 478 
measures in pulmonary arterial hypertension [103].  However, changes in 479 
the fractal dimension were found only in children with PAH, but not in 480 
adults [104]. Loss of distal vascular volume has also been described in  481 
patients with severe emphysema [105] and in patients with CTEPH [106]. 482 
 483 
 484 
CT evaluation of lung parenchyma 485 
CT is the gold standard for the evaluation of the lung parenchyma.  In a 486 
large registry series, CT measures have proven useful clinically in the 487 
assessment of patients with PAH [38]. Centrilobular ground glass opacities 488 
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are frequently seen in PAH and their presence on a CT performed for 489 
unexplained breathlessness should raise the possibility of this diagnosis 490 
[38, 107, 108].  Features of cardiac decompensation, pleural 491 
effusion/septal lines, and inferior vena caval size predict outcome [38]. The 492 
presence of emphysema or interstitial lung disease or bronchiectasis 493 
makes the diagnosis of pulmonary hypertension in association with lung 494 
disease likely. The addition of expiratory imaging is helpful to assess for 495 
small airways disease. CT may also identify features associated with rare 496 
conditions such as pulmonary veno-occlusive disease and pulmonary 497 
capillary haemangiomatosis (Section 2.2). This is an important differential 498 
diagnosis to idiopathic PAH because PAH therapy may be indicated but 499 
has a much higher risk of severe adverse effects than idiopathic PAH. 500 
 501 
CT evaluation of cardiac structure and function 502 
CT has historically not been used for the evaluation of cardiac structural 503 
abnormalities, as magnetic resonance imaging and echocardiography are 504 
the current modalities of choice. Nonetheless, many cardiac findings 505 
associated with pulmonary hypertension can be identified with non-gated 506 
contrast enhanced CT, including enlargement of cardiac chambers, 507 
thickening of the right ventricular free wall, and leftward deviation of the 508 
interventricular septum. CT can also identify structural abnormalities 509 
associated with congenital heart disease, such as partial anomalous 510 
pulmonary venous return and intracardiac shunts. Electrocardiogram-511 
gated CT can be used to quantitatively assess right and left ventricular 512 
function. Additionally, a decrease in distensibility of the main pulmonary 513 
artery is highly correlated with the presence of pulmonary arterial 514 
hypertension [109-111]. A study has shown that dynamic contrast 515 
enhanced CT can measure the transit of contrast, correlated with cardiac 516 
output [102], and is associated with the presence of pulmonary 517 
hypertension [101].  518 
 519 
CT evaluation of mediastinal structures  520 
CT provides detailed imaging within the mediastinum and may 521 
demonstrate findings that give information as to the etiology or severity of 522 
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pulmonary hypertension. Dilatation of bronchial arteries is a common 523 
finding in CTEPH (73%), but less common in other forms of pulmonary 524 
hypertension (14% in idiopathic PAH) [97, 112]. A dilated esophagus in the 525 
setting of pulmonary hypertension suggests the diagnosis of systemic 526 
sclerosis. Other mediastinal findings, while not specific to a given etiology, 527 
may suggest a poor prognosis. These include the presence of pericardial 528 
effusion, lymphadenopathy, and reflux of contrast into the hepatic veins 529 
[38]. 530 
 531 
1.5: Magnetic resonance imaging (MRI)   532 
 533 
Summary Statements: 534 
MRI enables comprehensive cardiac evaluation in patients with suspected 535 
pulmonary hypertension  536 
MRI is the gold standard technique for the assessment of biventricular 537 
morphology and function and is highly suitable for monitoring patients with 538 
pulmonary hypertension  539 
MRI provides prognostic value in pulmonary arterial hypertension 540 
MRI aids the classification of pulmonary hypertension particularly for left 541 
heart disease and chronic thromboembolic disease 542 
 543 
Cardiac magnetic resonance imaging (MRI) is the gold standard for 544 
quantification of right ventricular volumes, mass, function, and flow 545 
hemodynamics in the pulmonary circulation [113, 114]. Cardiac MRI 546 
techniques allow for non-invasive assessment of right ventricular function 547 
and structure using high spatiotemporal resolution imaging sequences with 548 
high accuracy and reproducibility without exposure to radiation [113]. 549 
Furthermore, cardiac MRI can be used for assessment of myocardial 550 
tissue deformation properties (strain), global structural evaluation, and 551 
perfusion [115-117].  552 
 553 
Right ventricular size and function 554 
Right ventricular hypertrophy and dilation reflect an increased afterload5. 555 
Particularly, in advanced stages of pulmonary hypertension, a severely 556 
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dilated and functionally compromised right ventricle has a negative effect 557 
on left ventricular diastolic function by means of leftward septal shift and 558 
reduced left ventricular filling associated with decreased right ventricular 559 
stroke volume. Indeed, both right and left ventricular dimensional metrics 560 
have been shown to have diagnostic potential in treatment naïve patients 561 
with pulmonary hypertension and prognostic value in both adult and child 562 
populations [118-120]. MRI derived bi-ventricular functional and volumetric 563 
indices have been shown to have independent prognostic potential and 564 
differentiated incidental treatment naïve and prevalent patients in a large 565 
group of patients (n=576) [121]. Cine MRI derived indices including 566 
interventricular septal bowing, left ventricular eccentricity, and ventricular 567 
dyssynchrony due to prolonged right ventricular contraction time have 568 
been shown to correlate with invasive hemodynamics and are reflective of 569 
the overall hemodynamic condition and disease severity [122, 123]. Septal 570 
deviation measured by MRI is useful for the diagnosis of PH, but also in 571 
patients with left heart disease septal deviation >160 degrees can identify 572 
patients with elevated diastolic pulmonary gradient [124]. In addition MRI 573 
has proven useful in the diagnosis of pulmonary hypertension in patients 574 
with COPD, typically a challenging cohort for echocardiography [125].  575 
 576 
Late gadolinium enhancement and T1 mapping 577 
Late gadolinium enhancement (LGE) imaging is used to identify focal 578 
myocardial pathology but has also been applied to investigate regional 579 
myocardial disease in the right ventricle as a response to elevated 580 
mechanical stress. The predominant focus has been on the right 581 
ventricular free wall insertion sites to septum and how the extent of LGE 582 
corresponds to right ventricular morphological and dynamic changes [44, 583 
45, 126-130]. Specifically, LGE was correlated with the reduced right 584 
ventricular function, dilation, mass, and regionally specific LGE was also 585 
inversely associated with reduced longitudinal strain [128, 131]. 586 
Additionally, the presence of delayed enhancement at the right ventricular 587 
insertion points has been associated with clinical worsening [127], though 588 
in a study using mortality as the end-point right ventricular insertion point 589 
LGE was not of independent prognostic significance. Extension of the LGE 590 
DOI: 10.1177_2045894019841990 
 
 21 
into the interventricular septum was of prognostic significance at univariate 591 
analysis but was not significant at multivariate analysis [45]. A limited 592 
number of studies have explored the role of coronary arterial flow in 593 
pulmonary hypertension. [117, 132]. Features may be seen in patients with 594 
pulmonary hypertension with LGE imaging, however, its utility in the 595 
routine assessment of suspected pulmonary hypertension is not proven. 596 
LGE imaging can be considered where intrinsic cardiac disease is 597 
suspected. 598 
 599 
T1 mapping is a quantitative method of assessing myocardial health. 600 
Native T1 mapping is performed without the use of contrast agents and 601 
has been shown to be an excellent differentiator between a healthy and 602 
diseased myocardium [133]. T1 has been shown to be elevated at the 603 
insertion points in pulmonary hypertension in animal [134] and human 604 
studies [135-137]. T1 correlates with markers of right ventricular 605 
remodeling [135] and septal position [138], however, no clear diagnostic or 606 
prognostic role has been identified in pulmonary hypertension [138].  607 
 608 
Right ventricular Strain 609 
Myocardial tissue deformation analysis has been assessed in patients with 610 
pulmonary hypertension [139-141]. Right ventricular morphology limits 611 
myocardial tagging and feature tracking to global longitudinal and 612 
circumferential deformation analysis. MRI based feature tracking has been 613 
shown to have prognostic potential and was associated with the severity of 614 
pulmonary hypertension [142]. Measuring left ventricular strain and torsion 615 
using tag MRI as part of ventricular interdependency and dyssynchrony 616 
investigations in CTEPH revealed left-right ventricular resynchronization 617 
post endarterectomy [143]. However, the clinical utility of deformation 618 
analysis is yet to be determined.     619 
 620 
Pulmonary artery and aortic flow measurements 621 
Phase-contrast MRI (PC-MRI) enables assessment of flow waveform in 622 
major vessels and allows for accurate Qp:Qs assessment, necessary in 623 
patients with suspected congenital lesions [114]. Phase-contrast MRI of 624 
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pulmonary flow is recommended for assessment of right ventricular stroke 625 
volume due to variable tricuspid regurgitation and the challenges of 626 
contouring the right ventricle [144]. Relative area change of the pulmonary 627 
artery has been shown to be of clinical value [145, 146], and recently has 628 
been shown to be independent of right ventricular measurements and 629 
clinical data [37]. Black blood slow flow has been shown to be a strong 630 
diagnostic marker as the flow characteristics of the main and branch 631 
vessels are visualized [147, 148]. Four-dimensional flow MRI (4D-Flow 632 
MRI) is an emerging technique allowing evaluation of flow, vorticity and 633 
kinetic energy in any region of interest. Vortices have been noted in the 634 
main pulmonary artery of patients with pulmonary hypertension. The 635 
lifetime of the existence of a vortex has been shown to correlate with mean 636 
pulmonary artery pressure, and may have utility in the identification of 637 
pulmonary hypertension [149-152]. 4D flow also has the additional benefit 638 
that it allows retrospective flow evaluation by selecting a 2D slice in any 639 
plane of the 4D data set [153], whereas current techniques rely on the 640 
slice positioning at the time of the scan.  641 
 642 
3D MR Perfusion and Angiography 643 
MR-angiography can show characteristic vessel patterns in subtypes of 644 
pulmonary hypertension, including pruning in idiopathic PAH, 645 
thromboembolic obstruction and stenosis in CTEPH, and splayed vessels 646 
in chronic obstructive pulmonary disease (COPD)/emphysema [113]. MR-647 
angiography is useful for the assessment of chronic embolus in the lobar 648 
and segmental pulmonary arterial vessels. Beyond the segmental level 649 
assessment of the pulmonary arteries with MR-angiography is very 650 
challenging [96]. In addition central embolus, particularly wall adherent clot 651 
can be missed if MR-angiography is reviewed in isolation, standard white 652 
blood MRI sequences can assist with visualization of central clot [96]. 653 
 654 
Dynamic contrast enhanced MRI perfusion is a promising technique for the 655 
assessment of chronic thromboembolic disease allowing visualization of 656 
pulmonary perfusion defects with sensitivity and specificity similar to that 657 
achieved with SPECT [39], with the advantages of higher spatial resolution 658 
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and lack of ionizing radiation. Time-resolved MRA or DCE can be used to 659 
measure passage of contrast bolus through heart and lungs to assess 660 
pulmonary perfusion [154, 155].  This can be used to measure mean 661 
transit time, time to peak, and blood volume [152, 156, 157]. 662 
 663 
1.6: Imaging in conjunction with invasive techniques 664 
 665 
Summary Statements: 666 
Catheter based angiography is used primarily to assess patients with 667 
chronic thromboembolic pulmonary hypertension considered as potential 668 
candidates for pulmonary endarterectomy or balloon pulmonary 669 
angioplasty 670 
Performance of catheter based angiography requires skilled operators and 671 
should generally be performed in a pulmonary hypertension referral centre 672 
Non-invasive imaging approaches can be used to select patients for 673 
pulmonary endarterectomy 674 
Imaging measurements combined with catheter measurements may be 675 
used to study right ventricular pressure and volume relationships  676 
 677 
Digital subtraction angiography 678 
Catheter based angiography involves rapid imaging of the pulmonary 679 
arteries during the injection of contrast material through a catheter placed 680 
into the pulmonary arterial system [158, 159]. This used to be the primary 681 
method for evaluation of the pulmonary vasculature. However, given the 682 
development of CT and MR methods these modalities can also be used 683 
[96, 106, 160]. Catheter based angiography may be used at expert 684 
institutions for the evaluation of chronic thromboembolism prior to 685 
pulmonary endarterectomy and is required for balloon pulmonary 686 
angioplasty. 687 
 688 
Assessment of ventricular-arterial coupling  689 
 690 
Imaging can be incorporated with invasive catheter based methods for 691 
characterization of the mechanics of the right ventricle and the pulmonary 692 
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arteries. Flow and volumetric MRI measurements in conjunction with 693 
pressures obtained from right heart catheterization can be used for 694 
assessment of ventricular-arterial coupling [161-163]. One method for 695 
determining right ventricular contractility involves computation of the 696 
pressure-volume loop while using balloon occlusion of the inferior vena 697 
cava, permitting a preload independent assessment of ventricular 698 
contractility [164]. In practice this method requires use of conductance 699 
catheters or the measurement of pressure and flow at the same time in 700 
order to construct the pressure volume loops with different degrees of 701 
preload modulated by the occlusion of the inferior vena cava. 702 
Conductance catheters typically require calibration of the volume signal 703 
from imaging, typically a baseline cardiac MRI. The “Single Beat” method 704 
using a cardiac catheter can be used to estimate Pmax. This has been 705 
used in conjunction with MRI to measure ventricular volumes and can 706 
serve as a surrogate for Ees/Ea [165], the relative utility of information 707 
from these methods remains an area of research [166].  Cardiac MRI has 708 
been used to measure stroke volume and right ventricular volumes and in 709 
conjunction with pressure measurements to construct pressure-volume 710 
loops, and estimate right ventricular contractility [167-169] [170]. An 711 
entirely MRI-based non-invasive method of measuring right ventricular to 712 
pulmonary artery coupling has been proposed, defined by right ventricular 713 
stroke volume/right ventricular end-systolic volume, however, this holds 714 
similar information to RVEF (right ventricular stroke volume / right 715 
ventricular end-diastolic volume)[171]. Studies have suggested added 716 
prognostic value of coupling measurments [172, 173] although a recent 717 
large study suggested it did not add additional prognostic significance over 718 
right ventricular volume alone in patients with PAH [121].   719 
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Section 2: Imaging adults with pulmonary hypertension 720 
 721 
2.1 The accuracy of cross sectional imaging to diagnose pulmonary 722 
hypertension and assess pulmonary haemodynamics 723 
 724 
Summary Statements 725 
 726 
A number of CT and MRI findings are characteristic of pulmonary 727 
hypertension  728 
Current qualitative approaches to imaging cannot be used to confidently 729 
exclude the presence of pulmonary hypertension 730 
Quantitative data obtained from imaging can be used to diagnose 731 
pulmonary hypertension and estimate pulmonary haemodynamics  732 
 733 
CT imaging is widely available and measurement of the pulmonary artery 734 
size has been shown to correlate with mean pulmonary artery pressure 735 
[174], however, in established pulmonary hypertension there are 736 
progressive increases in pulmonary artery size over time [175]. Pulmonary 737 
artery enlargement may be seen in interstitial lung disease in the absence 738 
of pulmonary hypertension [94], although a recent publication has shown 739 
equivalent diagnostic accuracy in patients with and without interstitial lung 740 
disease. In patients with systemic sclerosis in the absence of interstitial 741 
lung disease a ratio of main pulmonary artery to aortic diameter of at least 742 
1 was highly predictive of the presence of PAH although a normal ratio did 743 
not exclude PAH [176].   744 
 745 
MRI is non-invasive, reproducible and is considered the gold standard for 746 
assessing right ventricular function [177]. Studies have shown a high 747 
correlation between right ventricular mass and ventricular mass index 748 
(VMI), the ratio of right to left ventricular mass, and mean pulmonary artery 749 
pressure measured at cardiac catheterisation [178, 179]. Recently 750 
investigators have shown that combining VMI and septal curvature 751 
improves the accuracy of estimating mean pulmonary artery pressure 752 
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[180].  By using MRI to calculate left atrial volume pulmonary arterial 753 
wedge pressure PAWP can be estimated allowing calculation of the trans-754 
pulmonary gradient [180]. Cardiac output can be calculated from left 755 
ventricular volumetric measurements or phase contrast of flow in the 756 
pulmonary artery or aorta allowing an entirely non-invasive estimate of 757 
pulmonary vascular resistance based on individually derived MRI 758 
measurements. Models using right ventricular ejection fraction and 759 
average pulmonary artery velocity have also demonstrated accuracy for 760 
estimating catheter derived pulmonary vascular resistance [181]. Studies 761 
comparing CMR and right heart catheterisation in patients suspected of 762 
pulmonary hypertension have shown that an elevated VMI, reduced 763 
pulmonary artery velocity and the presence of increased gadolinium at the 764 
hinge points could predict the presence of pulmonary hypertension with a 765 
positive predictive value of >0.9 although no CMR measure could 766 
confidently exclude pulmonary hypertension [179]. In summary, although 767 
able to estimate pulmonary haemodynamics and identify pulmonary 768 
hypertension with high accuracy in certain groups, imaging is currently 769 
unable to exclude pulmonary hypertension.  770 
 771 
2.2 How helpful is imaging in identifying the cause of pulmonary 772 
hypertension and subtyping?  773 
 774 
Summary Statements 775 
Different forms of pulmonary hypertension and their subtypes may exhibit 776 
characteristic imaging features 777 
Echocardiography and MRI are useful for differentiation of pre and post 778 
capillary pulmonary hypertension 779 
CT provides an accurate evaluation of lung structural abnormalities 780 
Nuclear medicine, CT and MR perfusion imaging can be used to exclude 781 
chronic thromboembolic disease 782 
Different combinations of imaging modalities can be employed tailored to 783 
local expertise and availability.  784 
 785 
 786 
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Many of the imaging findings associated with pulmonary hypertension are 787 
common to most or all disease processes leading to pulmonary 788 
hypertension. These findings may include enlargement of the central 789 
pulmonary arteries, right-sided cardiac enlargement, and abnormalities of 790 
lung attenuation. Some imaging findings, however, are more specific and 791 
can help to distinguish among the various causes of pulmonary 792 
hypertension. These are discussed in the following section. 793 
 794 
Pulmonary Arterial Hypertension (group 1) 795 
Within group 1 PAH, imaging findings may suggest a specific aetiology. 796 
Patients with systemic sclerosis typically have a dilated oesophagus, a 797 
central ground glass pattern and often associated interstitial lung disease. 798 
Drug and toxin exposures may also be associated with mild parenchymal 799 
fibrosis or mosaic lung attenuation. In patients with portopulmonary 800 
hypertension, the presence of varices, features of liver cirrhosis and 801 
splenomegaly are frequent. Anomalous pulmonary venous drainage 802 
should be sought as this is frequently associated with congenital heart 803 
disease in particular a sinus venosus atrial septal defect which is difficult to 804 
detect by transthoracic echocardiography. An interatrial shunt may also be 805 
suggested by contrast visualized entering the left atrium via the interatrial 806 
septum. While enlargement of the pulmonary arteries is common to all 807 
forms of PAH, it is greatest in patients with Eisenmenger physiology [38]. 808 
Patients with Eisenmenger physiology may also have laminated proximal 809 
thrombus and calcification within the wall of pulmonary artery. Bronchial 810 
artery enlargement is most frequently observed in CTEPH but is also 811 
observed in patients with congenital heart disease [182] and patients with 812 
IPAH and a BMPR-2 mutation [183]. Pulmonary veno-occlusive disease 813 
(PVOD) is rare and is characterized by mediastinal lymphadenopathy and 814 
interlobular septal thickening [184, 185], with or without associated 815 
findings of alveolar edema, mediastinal lymphadenopathy in the setting of 816 
a normal sized left atrium. Pulmonary capillary hemangiomatosis (PCH) is 817 
frequently associated with nodular foci of parenchymal infiltration. The 818 
triad of peripheral interlobular septal thickening, centrilobular ground-glass 819 
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opacities, and mediastinal lymphadenopathy has a good association with 820 
PVOD and PCH [184, 186, 187]. 821 
 822 
Pulmonary hypertension due to left heart disease (group 2), 823 
pulmonary hypertension due to lung diseases (group 3), and 824 
pulmonary hypertension with unclear and/or multifactorial 825 
mechanisms (group 5) 826 
Within these groups, imaging may be useful to identify either left-sided 827 
cardiac enlargement (group 2) or diffuse lung disease (groups 3 or 5). 828 
Many lung diseases will have a distinctive radiographic appearance 829 
allowing for specific diagnosis and grading of severity. Characteristic 830 
structural features of patients with left heart disease which can be 831 
visualized on both CT and MRI include left atrial enlargement [188-190], 832 
absence of posterior displacement of the interventricular septum [179] and 833 
relatively normal right ventricular volumes, although right ventricular 834 
enlargement is seen in more severe disease particularly in the setting of 835 
severe tricuspid regurgitation. The presence of valvular and coronary 836 
artery calcification and evidence of previous cardiac surgery are more 837 
common in left heart disease although may also be present in patients with 838 
other forms of PH.  Echocardiography and MRI allow a comprehensive 839 
functional assessment. Patients with left heart disease have less right 840 
ventricular hypertrophy and compared to pre-capillary forms of pulmonary 841 
hypertension have better preserved right ventricular function. The absence 842 
of paradoxical septal motion / septal displacement in the setting of high 843 
right sided pressures infers an increase in left sided pressures. 844 
Echocardiography allows assessment of both systolic and diastolic 845 
dysfunction and the identification of valvular heart disease, in addition to 846 
identifying features suggestive of combined post- and pre-capillary disease 847 
[191].  848 
 849 
 850 
Chronic thromboembolic pulmonary hypertension (CTEPH) and other 851 
pulmonary artery obstruction (group 4) 852 
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A large prospective study estimated the risk of developing CTEPH after a 853 
pulmonary embolism at 3.8% at 2 years [192]. Imaging plays a critical role 854 
in the evaluation of suspected CTEPH, although the exact role of each 855 
imaging modality is debated. Some of this uncertainty reflects the rapid 856 
development of imaging technologies. Chest radiographs may suggest the 857 
diagnosis of CTEPH – with cardiomegaly, asymmetrical pulmonary artery 858 
enlargement, pruning of the vasculature and subpleural scarring – 859 
however, they are not diagnostic. Historically decisions on diagnosis and 860 
surgical management were based on V/Q scintigraphy and conventional 861 
pulmonary angiography with right heart catheterization. The role of V/Q 862 
scintigraphy (either planar or SPECT imaging) has changed. SPECT is 863 
recommended over planar imaging as it has higher diagnostic accuracy 864 
[193]. 865 
 866 
The current ESC/ERS guidelines recommend that V/Q scintigraphy be 867 
performed in all patients with suspected CTEPH [194]. These 868 
recommendations for V/Q scanning are in part based on clinical 869 
experience, previous recommendations and on older data [195-197]. This 870 
data demonstrated a significant improvement in the detection of CTEPH 871 
with scintigraphy compared to CTPA. However, rapid developments in CT 872 
technology have led to marked improvement in disease detection and 873 
characterization.  More recent studies in experienced centres demonstrate 874 
that CTPA has high diagnostic accuracy for CTEPH [39]. Key imaging 875 
findings include identification of eccentric thrombus, intravascular webs, 876 
stenoses with or without post stenotic dilatation and occlusions. Bronchial 877 
artery dilatation (commonly described as a diameter of >2mm) is more 878 
commonly seen than in other forms of pulmonary hypertension.  The 879 
presence of bronchial artery dilatation is associated with a better outcome 880 
following pulmonary endarterectomy. A mosaic perfusion pattern is seen in 881 
the vast majority of patients with CTEPH.  Its presence should alert the 882 
observer to the possibility of CTEPH but should be differentiated from the 883 
mosaic pattern seen in small airways disease where often single or small 884 
clusters of lobules are involved in contrast to larger geographical areas 885 
typically seen in CTEPH. Performance of expiratory CT may be helpful in 886 
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this setting.  Peripheral areas of sub-pleural scarring and cavitation 887 
representing healed infarcts may also be seen in approximately 10% of 888 
patients with CTEPH [198]. Dual-energy CT imaging generates maps of 889 
regional iodine density in the lung parenchyma as a surrogate for 890 
perfusion.  This may further improve the evaluation of suspected CTEPH 891 
by better demonstrating regions of decreased or absent blood flow [199], 892 
and has been shown to have excellent agreement with SPECT [200]. 893 
Although the availability of this technology is relatively limited, iodine 894 
mapping using CTPA with an unenhanced pre-scan is an emerging 895 
technique, which generates a lung perfusion map. In contrast to dual 896 
energy CT it does not require specialized hardware but involves 897 
subtraction of unenhanced images from the contrast enhanced study. This 898 
has the advantage that subtle abnormalities that may be missed on the 899 
angiography are unlikely to be overlooked on a perfusion map thus 900 
improving detection of subtle webs and distal disease [81].  901 
 902 
By providing an assessment of the lung parenchyma and the mediastinum 903 
CT can be helpful in identifying the presence of diffuse lung diseases and 904 
emphysema (groups 3 and 5) and excluding pulmonary vascular 905 
obstruction from a central mass. Parenchymal evaluation may also be 906 
valuable in identifying features suggestive of interstitial oedema, 907 
pulmonary veno-occlusive disease or vasculopathy though there is overlap 908 
in the imaging features. CT may also identify features suggestive of large 909 
vessel vasculitis or pulmonary artery sarcoma which may not be readily 910 
appreciated on projectional angiography.   911 
 912 
MR imaging can also provide an evaluation of the pulmonary vasculature 913 
and is increasingly being used in select centers for the evaluation of 914 
known or suspected CTEPH. 4D dynamic contrast-enhanced (DCE) lung 915 
perfusion magnetic resonance imaging (MRI) techniques [201] are widely 916 
available on current MRI systems and have shown excellent test 917 
performance in diagnosing CTEPH in a single centre registry setting [39] . 918 
In addition, a non-contrast, free breathing ventilation perfusion MRI 919 
technique, known as the Fourier Decomposition (FD)-MRI method [202, 920 
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203] has recently shown initial encouraging results in diagnosing chronic 921 
pulmonary embolism [204], however, this technique needs to be confirmed 922 
in larger multicenter studies. Combined cardiac MRI and time-resolved 923 
MRA exam is suitable for detailed treatment response evaluation before 924 
and after pulmonary endarterectomy as well as balloon pulmonary 925 
angioplasty (BPA) in CTEPH patients [205, 206] 926 
 927 
CTPA has largely replaced invasive catheter-based angiography as the 928 
initial morphological test for pulmonary arterial evaluation in most centers. 929 
However, catheter-based angiography may still have a role in the 930 
evaluation of CTEPH. Older data suggests that catheter-based 931 
angiography may provide a better assessment of the extent of pulmonary 932 
vascular obstruction than V/Q scintigraphy [207]. Additionally, some expert 933 
centers prefer catheter-based angiography for evaluation of the extent of 934 
thrombotic disease prior to PEA [208]. Again, CT performance relative to 935 
catheter-based angiography is generally poorer in older studies [159] 936 
compared to more recent data [209, 210] .  This difference again likely 937 
reflects significant advances in CT technique and technology as well as 938 
greater awareness of CTEPH and its imaging features in imaging circles.  939 
When there is diagnostic uncertainty regarding the extent and distribution 940 
of chronic thromboembolic changes on the basis of a single imaging 941 
modality (usually CT) the use of a second morphologic imaging modality 942 
(MR angiography or catheter based angiography) may prove 943 
complementary by improving confidence in subtle lesions or identifying 944 
others.  This can augment surgical decision making. 945 
 946 
In recent years balloon pulmonary angioplasty has emerged as an 947 
effective therapeutic modality in selected patients with CTEPH.  This has 948 
put greater emphasis on the evaluation of distal segmental and 949 
subsegmental vasculature. It is generally considered that at subsegmental 950 
level catheter based angiography out performs non-invasive morphological 951 
techniques (CT / MRI) which has resulted in increased utilization.  Clinical 952 
criteria and imaging algorithms for the selection of patients for BPA vary 953 
between centres but catheter based diagnostic angiography for potentially 954 
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suitable candidates permits confirmation of suitable extent and distribution 955 
of disease as well as the patients ability to tolerate a BPA procedure 956 
(ability to maintain breathhold and tolerate the required period on the 957 
catheter table) [211]. 958 
 959 
 960 
2.3 Echocardiography and Cardiac MR - what are the advantages and 961 
disadvantages of each modality?  962 
 963 
Summary statements 964 
Echocardiography is more widely available, lower in cost and more 965 
portable than MRI  966 
Echocardiography is superior to MRI for the evaluation of valvular heart 967 
disease and is more established in the assessment of diastolic function 968 
Magnetic resonance imaging provides more accurate quantitative 969 
assessment of right ventricular morphology and function 970 
Magnetic resonance imaging is more suited to serial assessment than 971 
echocardiography due to higher reproducibility 972 
 973 
Echocardiography and CMR provide value in the assessment of patients 974 
with pulmonary hypertension. Echocardiography is well established in the 975 
initial assessment of patients with suspected pulmonary hypertension. It 976 
has also been evaluated in the serial assessment of patients with 977 
pulmonary hypertension [66, 67] and has been found to be prognostic and 978 
is recommended in current guidelines at follow-up and following treatment 979 
change. 980 
 981 
Technical factors 982 
Echocardiography has high temporal resolution, is widely available, low in 983 
cost, portable and less affected by arrhythmia than MRI although real time 984 
imaging [212] has helped to counter this limitation at the cost of lower 985 
spatial resolution. Echocardiography is more operator dependent and is 986 
less reproducible. MRI has the advantage that it has better contrast 987 
resolution and is able to image in any plane making it more suited to 988 
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accurately quantify right ventricular morphology and function. Furthermore, 989 
contrast imaging allows assessment of focal abnormalities of the 990 
myocardium and an assessment of myocardial perfusion [113, 116]. 991 
 992 
Estimation of pulmonary haemodynamics  993 
In a systematic review of the literature the sensitivity and specificity for 994 
echocardiography for diagnosing pulmonary hypertension was 83% (95% 995 
CI, 73 to 90) and 72% (95% CI 53 to 85), respectively. However 996 
echocardiography is less accurate, in lung disease with sensitivity of 60% 997 
and specificity of 74% [213]. Empiric approaches have been used to 998 
estimate pulmonary haemodynamics using MRI [178, 180], In a recent 999 
study, mean pulmonary artery pressure was accurately estimated using 1000 
multivariate regression analysis of MRI indices, with ventricular mass 1001 
index and interventricular septal angle having additive value in model for 1002 
estimation of mean pulmonary artery pressure [180]. It has recently been 1003 
shown that with the inclusion of black blood pulmonary arterial slow flow in 1004 
addition to ventricular mass index and interventricular septal angle high 1005 
diagnostic accuracy can be improved further [147]. 1006 
 1007 
Right ventricular volumetric and functional assessment 1008 
Complete visualization of the right ventricle with echocardiography can be 1009 
challenging, particularly in lung disease, preventing a complete volumetric 1010 
evaluation of the right ventricle; this may be partially negated by the use of 1011 
3D echocardiography. MRI has the advantage of complete volumetric 1012 
evaluation of the cardiac chambers with good reproducibility of volume, 1013 
mass and ejection fraction [214] and is considered the gold standard for 1014 
serial assessment of right ventricular volume and function [215]. 1015 
Inaccuracies in segmentation of the right ventricle at the base of the heart 1016 
and segmentation of ventricular trabeculations may be improved using 1017 
threshold based approaches.  1018 
 1019 
Echocardiography, using pulsed wave and tissue Doppler, is an 1020 
established technique for the assessment of diastolic function. MRI phase 1021 
contrast evaluation of the mitral annulus is feasible [216] and in a small 1022 
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study imaging of the mitral valve annulus, in combination with mitral valve 1023 
and pulmonary venous flow was as accurate as echocardiography [217]. 1024 
Other techniques such as myocardial SPAMM tagging [218] and 4D three-1025 
directional velocity encoded MRI [219] have been used to evaluate left 1026 
ventricular diastolic function. Long analysis times may reduce the 1027 
applicability for routine clinical use.  1028 
 1029 
Valvular heart disease  1030 
Pulmonary hypertension may occur in the setting of valvular heart disease. 1031 
Echocardiography is the most useful non-invasive technique and has the 1032 
advantage over MRI that it has high temporal resolution and allows 1033 
accurate quantification of the severity of valvular heart disease. Left-sided 1034 
valvular heart disease is a common cause of group 2 pulmonary 1035 
hypertension. Contemporary studies suggest a prevalence of pulmonary 1036 
hypertension of 30-40% in patients with mitral stenosis [220] upwards of 1037 
30% in patients with severe mitral regurgitation [221];  in asymptomatic 1038 
patients, the presence of pulmonary hypertension serves as an indication 1039 
for valve surgery [222]. With the emergence of transcatheter aortic valve 1040 
replacement, pulmonary hypertension has been noted in up to 75% of 1041 
patients with severe aortic stenosis[223]. Currently, echocardiography is 1042 
the recommended non-invasive technique for the assessment of the 1043 
presence and severity of valvular disease given its advantages over MRI 1044 
including availability, low cost, high temporal resolution, widespread 1045 
experience over many years.  Despite this, there are instances in which 1046 
echo is limited due to poor acoustic windows, lack of agreement across 1047 
quantitative methods, significant inter- and intra-observer variability,  which 1048 
has led to interest in the emerging role of MRI in the assessment of 1049 
valvular heart disease [224, 225]. 1050 
 1051 
2.4 Can imaging replace cardiac catheterisation in the assessment of 1052 
suspected pulmonary hypertension? 1053 
 1054 
Summary statements 1055 
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Cardiac catheterisation is the gold standard for the measurement of 1056 
pulmonary artery pressure 1057 
CT and MRI may suggest the diagnosis of pulmonary hypertension and 1058 
quantitative MRI metrics can be used to confirm the presence of 1059 
pulmonary hypertension with high accuracy 1060 
At diagnosis MRI and cardiac catheterisation provide equivalent levels of 1061 
prognostic information  1062 
Cardiac catheterisation is currently the only way to identify patients with 1063 
idiopathic pulmonary arterial hypertension likely to benefit from calcium 1064 
antagonist therapy  1065 
 1066 
Current ESC/ERS guidelines [226] recommend right heart cardiac 1067 
catheterisation for the definitive diagnosis of pulmonary hypertension, 1068 
assessment of intra-cardiac shunting and vasodilator testing in selected 1069 
patients to identify the 10% of patients with idiopathic pulmonary arterial 1070 
hypertension who may benefit from high dose calcium antagonist therapy. 1071 
Measurements such as right atrial pressure, cardiac index and mixed 1072 
venous oxygen saturation have prognostic value [227-229], and serial 1073 
measurements are currently recommended to assess the response to 1074 
therapy [226]. The procedure requires meticulous attention to detail but in 1075 
expert hands is safe in adults with a morbidity of approximately 1% and 1076 
mortality of 0.055% [230], although the risk of complications is significantly 1077 
higher in children. Well established criteria at right heart catheter exist to 1078 
assess patients with idiopathic pulmonary arterial hypertension likely to 1079 
benefit from calcium antagonist therapy. However, no such criteria exist for 1080 
imaging metrics.  1081 
Although current guidelines discuss the role of CT and MRI in the 1082 
classification of pulmonary hypertension they are currently considered an 1083 
adjunct and not yet considered a replacement for right heart 1084 
catheterisation.  1085 
 1086 
2.5 What is the role of imaging in assessing prognosis and response 1087 
to treatment? 1088 
 1089 
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Summary statements 1090 
Echocardiography allows assessment of right ventricular function and 1091 
measurements such as right atrial area, right ventricular fractional area 1092 
change and tricuspid annular plane systolic excursion have prognostic 1093 
value 1094 
CT imaging provides prognostic information in pulmonary arterial 1095 
hypertension but its role in follow-up is currently limited by exposure to 1096 
radiation 1097 
A number of CMR metrics have prognostic value and changes in CMR 1098 
parameters at follow-up reflect changes in functional capacity and survival 1099 
Adjustment of right ventricular functional measurements for age and sex 1100 
improves prognostication 1101 
Changes in right ventricular function measured by MRI have prognostic 1102 
value 1103 
 1104 
Echocardiography is widely available and a number of metrics have been 1105 
shown to have prognostic value including right atrial area [231], right 1106 
ventricular fractional area change, TAPSE [232-234] and the presence of a 1107 
pericardial effusion [231, 235].  Echocardiography is widely used, in many 1108 
centres to assess the response to treatment, acknowledging issues of 1109 
operator dependency and reproducibility.  1110 
 1111 
Several measurements made at CTPA including right ventricular to left 1112 
ventricular ratio, right atrial size and a posteriorly deviated inter-ventricular 1113 
septum predict prognosis in PAH subgroups whilst the presence of pleural 1114 
effusions, septal lines and increased inferior vena cava area were 1115 
independent predictors of a worse outcome in PAH at presentation 1116 
regardless of subgroup [38]. Although this may be helpful at presentation 1117 
to guide urgent assessment and introduction of emergency therapies the 1118 
availability of other imaging modalities and associated radiation exposure 1119 
necessitates that CT is not recommended in the assessment of treatment 1120 
response.  1121 
 1122 
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In contrast, the highly reproducible nature and non-invasive and non-1123 
ionising nature of MRI makes it an ideal modality to assess treatment 1124 
response and in the EURO-MR study [236] changes in MRI measured 1125 
cardiac index and right ventricular ejection fraction correlated with changes 1126 
in WHO functional class and survival. A study examining changes in CMR 1127 
parameters demonstrated that this was a better predictor of outcome than 1128 
pulmonary vascular resistance measured invasively at cardiac 1129 
catheterisation [215]. MRI metrics including increased right ventricular 1130 
volumes, reduced left ventricular volumes, stroke volume, cardiac output 1131 
and pulsatility of the vasculature predict a worse outcome in PAH although 1132 
there is currently no large study comparing the prognostic value of CMR 1133 
and right heart catheter measures. 1134 
 1135 
2.6 How can we improve imaging techniques to make them more 1136 
acceptable to patients? 1137 
 1138 
Summary statements 1139 
Minimising radiation dose by the use of non-ionising techniques where 1140 
possible and implementation of dose reduction protocols will reduce the 1141 
risks to patients 1142 
Involvement of patients in investigative decision making will allow a more 1143 
tailored approach to investigation  1144 
 1145 
Whilst plain chest radiographs and echocardiography are generally well-1146 
tolerated and acceptable examinations, cross sectional techniques do 1147 
have some specific limitations and issues, in particular radiation doses 1148 
for CT and claustrophobia for MRI.  1149 
 1150 
The diagnostic information provided by CT needs to be balanced with the 1151 
radiation dose. In a life shortening illness concerns regarding radiation 1152 
exposure rarely impact on the decision to perform CT imaging at the time 1153 
of diagnosis. Advances in dynamic imaging, with improved temporal 1154 
resolution, has provided hope that gated CT can challenge MRI in the 1155 
assessment of cardiac function, however, such examinations typically 1156 
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involve higher doses of radiation. Using iterative reconstruction, dose 1157 
reduction can be achieved [237]. In fact, large reductions in dose to less 1158 
than a third the dose of standard acquisitions have been achieved 1159 
without loss of image quality using iterative reconstruction [238], and the 1160 
use of dynamic Z axis collimation has been shown to further reduce dose 1161 
[239].  1162 
 1163 
Limitations of MRI include long scanning times, scanner noise and 1164 
frequently patients feel claustrophobic (5%) leading to incomplete 1165 
examinations. Developments to reduce scanning time, eg. novel rapid 1166 
imaging techniques and limiting the study to the most clinically relevant 1167 
sequences may help. The more widespread installation of wide bore 1168 
scanners may help to reduce claustrophobia and make MRI a more 1169 
acceptable imaging modality for all patients. The use of media 1170 
entertainment may improve acceptability to patients.  More patient 1171 
involvement in discussions around the implications of the tests are 1172 
needed. Patient participation is advised to determine the issues most 1173 
relevant to patients to help develop imaging services.  1174 
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Section 3 Imaging pathway for suspected pulmonary 1175 
hypertension in adults 1176 
 1177 
3.1 Current guidelines 1178 
 1179 
The ESC/ERS guideline on diagnostics and therapy of pulmonary 1180 
hypertension review current imaging modalities and make a number of 1181 
recommendations for incorporation in a diagnostic strategy [2]. 1182 
Echocardiography is recommended as a first-line non-invasive diagnostic 1183 
investigation in case of suspicion of pulmonary hypertension. Chest x-ray 1184 
and high-resolution CT are recommended in patients with high or 1185 
intermediate probability of pulmonary hypertension following 1186 
echocardiography and high-resolution CT should be considered in all 1187 
patients with pulmonary hypertension. Ventilation/perfusion or perfusion 1188 
lung scan is recommended in patients with unexplained pulmonary 1189 
hypertension to exclude CTEPH. Contrast CT angiography of the 1190 
pulmonary arterial circulation is recommended and pulmonary (catheter 1191 
based) angiography should be considered in the workup of patients with 1192 
CTEPH. There are no recommendations for the use of MR imaging as part 1193 
of the diagnostic strategy or algorithm and no  discussion of  emerging 1194 
techniques [240] [241] . Current American College of Chest Physicians 1195 
guidelines on pulmonary hypertension provide no specific 1196 
recommendations on employing imaging as part of a diagnostic strategy in 1197 
patients with suspected pulmonary hypertension [242].  1198 
The Cologne Consensus Conference 2016 provides no additional imaging 1199 
guidelines. 1200 
 1201 
3.2 PVRI diagnostic imaging pathway (Figure 1) 1202 
 1203 
Initial assessment and identification of risk factors 1204 
In patients presenting with symptoms and or signs suggestive of 1205 
pulmonary hypertension a detailed history and the results of basic tests 1206 
are key in determining the diagnostic strategy. Risk factors for treatable 1207 
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forms of pulmonary hypertension (PAH and CTEPH) must be sought as 1208 
their presence reduces the threshold for further imaging. Basic 1209 
investigations including an electrocardiogram, lung function with gas 1210 
transfer factor and a plain radiography may suggest an alternative 1211 
diagnosis [194] or increase the probability of pulmonary hypertension.  1212 
Further investigation may not be required when a confident alternative 1213 
diagnosis can be made.  1214 
 1215 
Echocardiograpy 1216 
Echocardiography is the recommended first line imaging modality in the 1217 
assessment of suspected pulmonary hypertension and allows evaluation 1218 
of cardiac structure and function and an estimate of pulmonary artery 1219 
pressure.  Following echocardiography, patients should be stratified into 1220 
those at low, high or intermediate probability of pulmonary hypertension 1221 
according to ESC/ERS guidelines [194].  1222 
 1223 
Sub-optimal echocardiography 1224 
For patients with a sub-optimal echocardiogram, imaging with CMRI can 1225 
be used to identify patients at increased risk of pulmonary hypertension 1226 
although currently used metrics cannot confidently exclude mild pulmonary 1227 
hypertension [147]. A number of metrics on CTPA have been shown to 1228 
reflect elevated pulmonary artery pressures in addition to providing 1229 
information on other potential causes for breathlessness, and although 1230 
evidence is limited this may be considered in selected patients [91, 95]. 1231 
 1232 
Low probability of pulmonary hypertension from echocardiography 1233 
For symptomatic patients identified as low probability from 1234 
echocardiography, further assessment is dependent on the presence or 1235 
absence of risk factors. For those with risk factors for CTEPH, perfusion 1236 
lung imaging is recommended using CT imaging (CT-LSIM of DECTA), 1237 
nuclear medicine techniques (ideally SPECT), or MRI perfusion imaging 1238 
[39, 81, 86, 243].  If risk factors for PAH exist, the diagnostic strategy will 1239 
be dependent on the risk factor; in systemic sclerosis, given the high 1240 
prevalence of PAH in symptomatic patients, further evaluation is advised 1241 
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and a number of screening regimens exist such as DETECT [244]. For 1242 
other at risk patients an interval echocardiographic examination may be 1243 
appropriate [194]. 1244 
 1245 
High or intermediate probability of pulmonary hypertension from 1246 
echocardiography and assessment for left heart disease 1247 
For patients at intermediate or high probability of pulmonary hypertension, 1248 
the echocardiogram should be evaluated for evidence of left heart disease 1249 
such as significant valvular heart disease, left ventricular systolic or 1250 
diastolic dysfunction. If present the history should be re-reviewed to 1251 
assess for risk factors for left heart disease (hypertension, obesity, 1252 
coronary artery disease, diabetes mellitus, atrial fibrillation). Where risk 1253 
factors for PAH or CTEPH are absent and risk factors for left heart disease 1254 
present, pulmonary artery pressure modestly elevated, left atrial size 1255 
increased, no paradoxical septal motion and / or significant right 1256 
ventricular dysfunction present, then no further investigation to assess for 1257 
pulmonary hypertension may be required. However, where risk factors for 1258 
PAH or CTEPH are present, right ventricular function is severely impaired, 1259 
systolic pulmonary artery pressure is severely elevated (≥70 mmHg) and  1260 
/ or paradoxical septal motion exists, then further investigation to exclude 1261 
other causes of pulmonary hypertension should be considered [26]. If no 1262 
features of left heart disease exist patients should undergo CT pulmonary 1263 
angiography if no contraindications exist. 1264 
 1265 
CT pulmonary angiography  1266 
Where left heart disease is excluded or if present and other causes of 1267 
pulmonary hypertension cannot be confidently excluded, then cross 1268 
sectional imaging with CT including CT pulmonary angiography should be 1269 
considered as it can aid in  (i) assessment of the likelihood of pulmonary 1270 
hypertension, (ii) classification of disease (identifying features of co-1271 
existing lung disease or left heart disease) and (iii) identification of patients 1272 
with CTEPH [38]. If features of CTEPH are identified at this stage, patients 1273 
should be referred directly to a centre experienced in the management of 1274 
pulmonary hypertension for further evaluation.  1275 
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 1276 
Perfusion lung imaging 1277 
If CTPA is sub-optimal, indeterminate, or is performed by a centre not 1278 
experienced in the assessment of pulmonary hypertension and CTEPH is 1279 
not identified, in the absence of significant parenchymal lung disease, 1280 
perfusion lung imaging (Q-SPECT of 3D MR perfusion) is advised at this 1281 
stage. CT lung subtraction iodine mapping (CT-LISM) or dual energy CT 1282 
(DECT) in addition to directly visualising abnormalities in the pulmonary 1283 
arterial tree also allows construction of perfusion lung maps, preventing 1284 
the need for other forms of perfusion lung imaging to exclude CTEPH [81, 1285 
86, 199, 245]. 1286 
 1287 
Where patients have rapidly progressive symptoms and a high probability 1288 
of pulmonary hypertension from echocardiography, physicians should not 1289 
delay referral to expert centres until the above investigations are 1290 
completed. Supplementary investigations including tests to assess for 1291 
conditions associated with PAH such as connective tissue disease and 1292 
HIV infection should be considered [1, 194]. 1293 
 1294 
Review and integration of imaging investigations with other tests and 1295 
assessment for respiratory disease 1296 
Following imaging, the results should be integrated with the patient’s 1297 
clinical characteristics. CT imaging may identify unexpected findings such 1298 
as thromboembolic disease or parenchymal lung disease. Given the 1299 
current lack of evidence for specific interventions targeting the pulmonary 1300 
vasculature for patients with pulmonary hypertension in the context of 1301 
respiratory disease current therapies should be aimed at the underlying 1302 
condition, recognizing that the presence of pulmonary hypertension 1303 
identifies patients at increased risk of death; where appropriate options 1304 
such as transplantation should be explored. In patients with respiratory 1305 
disease with risk factors for PAH or CTEPH,  significant right ventricular 1306 
dysfunction or severe elevation in systolic pulmonary artery pressure 1307 
(≥70mmHg), referral to a PH centre should be considered; selected 1308 
patients may be entered into studies or receive a trial of therapy. In 1309 
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addition to pulmonary vascular phentoypes increasingly recognized in 1310 
respiratory disease [4, 246, 247], these patients may have other forms of 1311 
pulmonary hypertension such as undiagnosed connective tissue disease 1312 
or CTEPH [247]. Where uncertainty exists, discussion or referral to a 1313 
pulmonary hypertension centre is recommended. 1314 
 1315 
Referral or discussion with a pulmonary hypertension referral centre 1316 
Pulmonary hypertension referral centres provide an environment where 1317 
specialists are experienced in the assessment of patients with suspected 1318 
pulmonary hypertension. They also provide specific therapies and support 1319 
for people affected by pulmonary hypertension. Imaging investigations will 1320 
be reviewed and where sub-optimal may be repeated. At this stage further 1321 
investigation will usually be dependent on the pre-test probability of 1322 
different forms of pulmonary hypertension. See Table 1. For patients 1323 
considered for treatment, cardiac catheterization is recommended. 1324 
 1325 
CTEPH suspected  1326 
For those with evidence of CTEPH on CTPA or with risk factors such as 1327 
previous pulmonary embolus, deep venous thrombosis, splenectomy, or 1328 
pacemakers, further evaluation of (i) the pulmonary vasculature with DSA 1329 
or MRA, (ii) lung perfusion, with SPECT or 3DMR perfusion, DECTA/CT-1330 
LISM, (iii) lung ventilation, (iv) biventricular function, with CMR or 3D echo 1331 
and (v) coronary or further cardiac valvular assessment,  if risk factors for 1332 
ischaemic heart disease exist or co-existant valvular heart disease is 1333 
noted, and the patient is considered a candidate for pulmonary 1334 
endarterectomy, may be performed. The choice of investigations are also 1335 
dependent on the preference of pulmonary hypertension referral centre, 1336 
where pulmonary endarterectomy or balloon pulmonary angioplasty, is 1337 
being considered. Right heart cardiac catheterisation with measurement of 1338 
pulmonary arterial wedge pressure and pulmonary vascular resistance will 1339 
aid decisions regarding appropriateness of the intervention and to confirm 1340 
the presence of pulmonary hypertension. Where filling defects extend into 1341 
the proximal pulmonary artery and or right ventricular outflow tract other 1342 
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conditions such as sarcoma should be considered and FDG-PET-CT may 1343 
be helpful [248, 249]. 1344 
 1345 
Patients with risk factors for specific forms of pulmonary 1346 
hypertension 1347 
In patients with risk factors for specific forms of PAH, further investigation 1348 
should be tailored; ultrasound examination of the liver with portal Doppler 1349 
ultrasound should be performed in patients suspected of underlying liver 1350 
disease / portal hypertension. In cases where congenital heart disease is 1351 
suspected (features such as anomalous pulmonary venous drainage or 1352 
atrial septal defect may have been detected on CT or transthoracic 1353 
echocardiography), transoesophageal echocardiography and or CMRI to 1354 
estimate Qp:Qs ratio and cardiac catheterisation with a saturation run 1355 
should be considered [250, 251]. In patients with PH where the cause is 1356 
felt to primarily related to left heart disease or respiratory disease right 1357 
heart catheterization may be required to assess disease severity 1358 
particularly if a trial of treatment is contemplated. Further assessment of 1359 
right ventricular function in these patients may be helpful, particularly 1360 
where the echocardiographic assessment of right ventricular function was 1361 
challenging;  findings at cardiac MRI of preserved or mildly impaired RV 1362 
function or a normal septal angle in PH-LHD (suggesting the absence of a 1363 
pre-capillary component) may negate the need for right heart 1364 
catheterization [124].  1365 
 1366 
Unexplained pulmonary hypertension 1367 
Where no obvious cause of pulmonary hypertension exists, following 1368 
review of imaging and integration with other clinical characteristics, cardiac 1369 
catheterisation with vasodilator testing should be performed to identify the 1370 
10% of patients with idiopathic PAH who have a fall in mean pulmonary 1371 
artery pressure or at least 10 mmHg to <40 mmHG with no reduction in 1372 
cardiac output, who may respond to treatment with high dose calcium 1373 
channel blockers [194].  1374 
 1375 
Unexplained hypoxaemia 1376 
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Hypoxaemia in pulmonary hypertension is uncommon at the time of 1377 
diagnosis in the absence of respiratory disease, a right to left shunt or a 1378 
severely reduced gas transfer factor. If a right to left shunt is suspected a 1379 
bubble echocardiogram, renal perfusion SPECT or MRI (time resolved 1380 
imaging or Qp:Qs) should be considered. 1381 
 1382 
Monitoring of patients at follow-up 1383 
Following diagnosis follow-up assessments of right ventricular function are 1384 
recommended to aid risk stratification [119, 215] in combination with a 1385 
clinical assessment and a measurement of exercise capacity. Cardiac MRI 1386 
or echocardiograpy can be used to assess right ventricular function. In 1387 
selected cases follow-up cardiac catheterization may be performed. 1388 
 1389 
  1390 
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Section 4.0: Imaging children with suspected pulmonary 1391 
hypertension 1392 
 1393 
Summary statements 1394 
Echocardiography is recommended as the initial imaging investigation in 1395 
children with suspected pulmonary hypertension 1396 
Performance of cardiac catheterization in children frequently requires 1397 
general anaesthesia and is associated with a higher risk of complications 1398 
than in the adult population 1399 
Diagnostic imaging strategies differ in children compared to adults 1400 
reflecting significant differences in disease aetiology 1401 
MRI is of additional value in the initial evaluation and follow-up of 1402 
pulmonary hypertension in conjunction with other non-invasive techniques 1403 
such as echocardiography. 1404 
Imaging techniques should be modified where possible to provide 1405 
adequate diagnostic information whilst avoiding anaesthesia.  1406 
 1407 
4.1 Introduction 1408 
Imaging provides valuable information that aids the management of 1409 
patients with pulmonary hypertension, from diagnosis and accurate 1410 
phenotyping, through to monitoring disease and assessing response to 1411 
therapy.  The majority of imaging modalities in medicine and their 1412 
implementation in hospital environments have been developed with the 1413 
needs of adult patients in mind. Whilst the underlying philosophy and 1414 
principles of imaging in children are the same as in adult pulmonary 1415 
hypertension there are some challenges which may be more pertinent to 1416 
imaging children.  With appropriate modification these can be overcome. 1417 
 1418 
4.2 Differences in the spectrum of disease between adults and 1419 
children:  1420 
Whilst pulmonary vascular disease pathophysiology is very similar, the 1421 
context in which it occurs in children is often very different to adult cohorts 1422 
of pulmonary hypertension.  Most notably children are much more likely to 1423 
have pulmonary hypertension in the context of congenital or 1424 
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developmental abnormalities whereas in adult populations comorbid 1425 
diseases of aging may be more important.  Large cohorts of paediatric 1426 
patients with pulmonary hypertension demonstrate that pulmonary 1427 
hypertension related to congenital heart disease and pulmonary 1428 
hypertension related to developmental lung disorders predominate with 1429 
idiopathic pulmonary arterial hypertension responsible for approximately 1430 
20% of published cohorts and chronic thromboembolic pulmonary 1431 
hypertension responsible for less than 1% of cases.[252]  Furthermore 1432 
approximately 30% of children with pulmonary hypertension have more 1433 
than one potentially causal association.[253]   Finally, in a large proportion 1434 
of children with pulmonary hypertension the pulmonary hypertension is 1435 
associated with other rare conditions.   Taken together this means that the 1436 
pre-test probabilities of different pulmonary hypertension aetiologies differs 1437 
from that in adults.  This in turn affects the overall diagnostic imaging 1438 
strategy. A diagnostic algorithm for children has recently been published 1439 
following the World symposium of pulmonary hypertension, and reflects 1440 
differences between adults and children.[254] 1441 
 1442 
4.3 Scale 1443 
The paediatric period covers a period from birth to adulthood.  The body 1444 
undergoes enormous growth and development during this period of time 1445 
and body size can increase by almost two orders of magnitude.  Organ 1446 
structure, function, maturity and complexity continue to develop through 1447 
childhood and again enormously during puberty, profoundly affecting 1448 
physiology. 1449 
 1450 
The most obvious change through childhood is in size.  This produces 1451 
challenges when aiming to distinguish normal organ size from abnormal, 1452 
for example ventricular volume.  A number of approaches have been 1453 
adopted to address this challenge.  The first is to establish normative data 1454 
for children throughout childhood and express these in terms of centile 1455 
charts or standard deviation (Z) scores.  Normative values in 1456 
echocardiography in large populations of healthy children are increasing 1457 
with normative echocardiographic values published in pediatrics with 1458 
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Boston z-scores.[255, 256]  Normative values in cardiac MRI in large 1459 
populations of healthy children is challenging and normative data are 1460 
sometimes lacking.  A second approach is to adopt ratio-metric 1461 
relationships, that is, the parameter in question is simply divided by a 1462 
measure of body size e.g. BSA or is expressed as a ratio against another 1463 
cardiovascular parameter in the same patient, e.g. pulmonary artery to 1464 
aorta size ratio; yet these approaches have significant limitations.  A more 1465 
appropriate and physiologically sound approach to scaling may be to 1466 
adopt allometric scaling relationships.  This approach divides the 1467 
cardiovascular variable of interest by the body size variable raised to a 1468 
scalar exponent in the form x/yb .  There are data across a huge range of 1469 
scales and species which show empirically that this approach eliminates 1470 
the effect of body size on cardiovascular structure and function.  This 1471 
approach to scaling or normalisation has not been widely adopted and 1472 
therefore the relevant scaling exponents are not well established or 1473 
accepted.   1474 
 1475 
The effect of scale on imaging resolution 1476 
By definition, in children spatial scales of structures are smaller (i.e. 1477 
children are smaller) and temporal scales are typically shorter (i.e. children 1478 
have higher respiratory rates and higher heart rates).  This therefore 1479 
affects imaging quality at any given spatio-temporal resolution. While 1480 
some adaptations are possible for example higher frequency ultrasound 1481 
probes for echocardiography other imaging modalities suffer from 1482 
fundamental physical and engineering limits to their spatial temporal 1483 
resolution.  Table 2 suggests some approaches which may improve spatio 1484 
temporal resolution of imaging modality such that they are suitable for 1485 
smaller patients.  1486 
 1487 
4.4 Intellectual/emotional maturity 1488 
Many imaging modalities require the cooperation of the patient to achieve 1489 
optimal imaging results.  Children are often emotionally and intellectually 1490 
less mature than adults, thus securing their cooperation can be more 1491 
challenging and time-consuming.  One approach to this which is widely 1492 
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used is to sedate or anaesthetise children, however, sedation and 1493 
anaesthesia in children with pulmonary hypertension is associated with a 1494 
substantial risk of morbidity and mortality and it is desirable to avoid this 1495 
wherever possible.  Imaging in an appropriate environment with adequate 1496 
time and support, e.g. play therapist involvement, time to familiarize 1497 
patients with the environment can substantially improve cooperation and 1498 
imaging quality. Distraction techniques and allowing parents into the 1499 
imaging room are extremely helpful.   1500 
 1501 
4.5 Echocardiography in Pediatric Pulmonary Hypertension 1502 
Echocardiography is used as the initial screening diagnostic imaging for 1503 
the diagnosis of paediatric pulmonary hypertension and the most important 1504 
non-invasive tool that is used for routine assessment. [47, 48, 252, 257-1505 
259]  It is used for continued follow-up and medication management.[260]  1506 
Developments in echocardiography in the past two decades have led to 1507 
new insights into the structure and function of the right ventricle and its 1508 
role in various diseases including pulmonary hypertension.[261, 262]   1509 
Conventional imaging includes assessment of anatomy in two-dimensions 1510 
(2D), hemodynamics via Doppler echocardiography, and qualitative and 1511 
quantitative evaluation of right ventricular (RV) and left ventricular (LV) 1512 
function.[47, 48, 258, 260, 263-265]  Advanced echocardiography includes 1513 
evaluation of right heart size and function, myocardial mechanics, and 1514 
estimated RV to pulmonary arterial (PA) coupling ratio.[266-270]   Table 3 1515 
shows the advantages and limitations of each of echocardiographic 1516 
techniques used in paediatric pulmonary hypertension.  In recent years, 1517 
different echocardiography parameters have been found in small studies 1518 
to be useful in identifying high-risk patients who are likely to develop 1519 
adverse clinical outcomes [269, 271-274].  Table 4 demonstrates the 1520 
echocardiographic views needed to obtain the functional parameters in 1521 
paediatric pulmonary hypertension.   1522 
 1523 
4.6 Cardiac Magnetic Resonance Imaging in Pediatric Pulmonary 1524 
Hypertension 1525 
DOI: 10.1177_2045894019841990 
 
 50 
Cardiac MRI remains the gold standard imaging modality for assessment 1526 
of bi-ventricular function and volumes in pediatric pulmonary 1527 
hypertension.[252]  MRI derived functional and volumetric indices predict 1528 
morbidity and mortality in pediatric pulmonary hypertension and may 1529 
provide additional information with respect to inter-ventricular interactions 1530 
[120, 275]. In addition, phase-contrast MRI remains the state-of-the-art 1531 
flow imaging technique enabling precise flow volume quantification and 1532 
consequently provides valuable assessment of Qp/Qs ratios in children 1533 
with pulmonary hypertension associated with congenital heart disease and 1534 
intracardiac shunts.  Furthermore, parallel or sequential phase-contrast 1535 
MRI and pressure evaluation in the catheterisation lab has been proposed 1536 
as a novel and potentially more reliable method for the calculation of 1537 
pulmonary vascular resistance in comparison to standard Fick principle or 1538 
thermodilution [276, 277].  Recent studies suggest that pulsatile pulmonary 1539 
vascular stiffness indices derived by phase-contrast MRI and ultrasound 1540 
may have a strong prognostic potential to predict both hard and soft 1541 
outcomes in pediatric pulmonary hypertension [278-280].  Lastly, MRI 1542 
angiography can aid with differential diagnosis by fine characterization of 1543 
the pulmonary vasculature and exclusion of thrombi. Unlike 1544 
echocardiography, cardiac MRI is currently not suitable for frequent serial 1545 
assessment due to its clinical availability, longer post-processing time, and 1546 
also due to necessary anesthesia required for younger children and 1547 
neonates.   1548 
 1549 
In summary, children pose a different set of challenges to adult 1550 
populations when it comes to imaging.  Given the proven benefits of 1551 
imaging adults with pulmonary hypertension it is appropriate that all 1552 
patients including children are allowed to experience these benefits.  1553 
Appropriate adaptations to imaging strategy and environment can achieve 1554 
high quality results in the vast majority of paediatric patients. 1555 
 1556 
 1557 
 1558 
 1559 
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Section 5 Future Directions 1561 
 1562 
5.1 Applications of computational modelling and AI in pulmonary 1563 
hypertension 1564 
 1565 
Summary statements 1566 
Physiological modelling can be used to characterise the behavior of the 1567 
cardiopulmonary system. 1568 
Computational models assessing pulmonary artery flow have high 1569 
diagnostic accuracy in suspected pulmonary hypertension 1570 
Machine learning approaches may assist image segmentation and improve 1571 
diagnostic and prognostic assessments. 1572 
Further work to assess computational approaches versus current diagnostic 1573 
approaches in pulmonary hypertension is recommended. 1574 
 1575 
Imaging modalities and markers derived based on images alone have 1576 
been shown to have clinical potential. Their interpretation could be 1577 
enriched by introducing additional knowledge from the application of 1578 
mathematical models, which can bring insights into the haemodynamic 1579 
system behaviour in health and disease.  1580 
 1581 
Based on mathematical and physical principles, models of the pulmonary 1582 
circulation are currently being evaluated in the translational/clinical 1583 
research. Electrical analogue (Windkessel or 0D-zero-dimensional) 1584 
models supplied by patient-specific 2D phase-contrast MRI data have 1585 
been proposed [281, 282] to globally characterise the pulmonary 1586 
circulation in terms of vascular resistance and compliance in healthy and 1587 
PH patients. They have also shown promising results for quantifying the 1588 
changes of the electric parameters in patients with PAH, at baseline and 1589 
follow-up [283]. Wave transmission (one dimensional 1D) models are 1590 
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particularly powerful, as “waves carry information”, and the energy [282, 1591 
284, 285] contained in the backward reflected wave can be used as an 1592 
indicator between the right ventricle and its afterload mismatch. Using a 1593 
1D model of a straight elastic tube and temporal MRI flow and area 1594 
waveforms, it has been shown that on average, more than 40% of the total 1595 
wave power was contained in the backward wave measured in patients 1596 
with PH, whereas less than 20% was characteristic to the healthy 1597 
volunteers group [282]. Different PH heterogeneities can be mimicked by 1598 
modifying the structural and elastic parameters of a 1D pulmonary tree 1599 
structure. Several authors [285-287], investigated the pressure and flow 1600 
waveforms in healthy and several simulated PH conditions, using 1601 
numerical solutions of 1D models of the major vessel network. Notably, 1602 
Qureshi et.al [285] changed the configuration of the structured tree and 1603 
altering, in turn, the compliance of the large and small vessels to predict 1604 
the haemodynamic changes induced by PAH, CTEPH and HLD. The 1605 
authors showed an increase in the reflected waves under these simulated 1606 
conditions, with the potential to differentiate between different PH 1607 
phenotypes.  1608 
 1609 
The 0D and 1D models have the main advantage that are relatively simple 1610 
to implement and do not require significant computing resources. 1611 
However, three-dimensional, 3D computational fluid dynamics (CFD) 1612 
models are more complex, being able to provide patient-specific 1613 
characterisation of haemodynamics [288, 289]. Full 3D CFD simulations 1614 
can resolve the physiological flow field in all three directions and time. 1615 
Further post-processing of the CFD results can provide computed metrics 1616 
(for example wall shear stress (WSS)), which give additional insights on 1617 
disease progression. It has been argued [290] that pathological flows in 1618 
the pulmonary artery alter cell behaviour favouring vasoconstriction. 3D 1619 
CFD [291, 292] studies of the pulmonary circulation showed that shear 1620 
stress has an impact on endothelial health and dysfunction, and reduced 1621 
WSS in the proximal pulmonary arteries were shown to be characteristic to 1622 
PH patients.  1623 
 1624 
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Machine learning of RV contours to derive tissue motion has shown to be 1625 
of prognostic value in PAH and of greater significance than standard 1626 
cardiac volumetric metrics [293]. Such approaches are of great potential, 1627 
minimizing user input / error and potentially providing a more complete 1628 
prognostic assessment. The added value versus measurements adjusted 1629 
for age, sex and body surface area [118, 294], or standard CMR strain 1630 
parameters in PAH is an area for further work. Machine learning 1631 
approaches may significantly improve the automation and quantification of 1632 
parameters from imaging. For example, deep learning approaches have 1633 
already been utilized for automation of arterial-venous segmentation of the 1634 
pulmonary circulation [295]. 1635 
 1636 
The success of the computational models is closely related to the available 1637 
data from the imaging modalities. Regardless of using the data only to 1638 
supply the models’ boundary conditions, or integrate it within artificial 1639 
intelligence algorithms [296, 297], the computational models and imaging 1640 
modalities play together an essential role in the process of non-invasive 1641 
PH diagnostic, prognostic and understanding of the disease mechanisms.  1642 
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Section 6 Conclusion and areas of research priority 1643 
 1644 
In this statement we have discussed recent advances in imaging 1645 
techniques in pulmonary hypertension and  their clinical application.  This 1646 
is summarised in the PVRI Imaging Task Force diagnostic algorithm. 1647 
Rapidly evolving technologies also provide opportunities to improve our 1648 
understanding of pulmonary hypertension and assess the impact of much 1649 
needed new therapies. This section identifies areas requiring further 1650 
research in addition to highlighting a number of on-going and planned 1651 
studies. 1652 
 1653 
6.1 Establishment of normative ranges and repeatability of imaging 1654 
techniques  1655 
Despite the widespread use of imaging techniques in clinical practice there 1656 
is only limited data on the impact of age, sex and ethnicity on commonly 1657 
used metrics. The studies conducted to develop normative equations to 1658 
allow for correction have been performed [298-304]. However, given the 1659 
significant impact of age, sex and ethnicity on morphological 1660 
characteristics, more research in this area is warranted to understand 1661 
variation across populations.  1662 
 1663 
There is increasing interest in using imaging end-points in clinical trials to 1664 
assess treatment response in the clinic setting. However, there is limited 1665 
data on the repeatability of cardiac MRI measurements. The RESPIRE 1666 
study (clinicaltrials.gov), which should report in the 3rd quarter of 2019 will 1667 
provide information on the sensitivity to change relative to measurement 1668 
repeatability of cardiac MRI morphological and functional data. This will aid 1669 
the design of studies considering MRI as a primary end-point.  Even in the 1670 
absence of such data, studies such as REPAIR (clinicaltrials.gov) are now 1671 
using imaging to assess the impact of pharmacological interventions. The 1672 
results of these studies are awaited with interest.     1673 
 1674 
6.2 Comparison of imaging modalities and approaches 1675 
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There are pros and cons of different imaging modalities with respect to 1676 
diagnostic performance, repeatability, availability, exposure to ionising 1677 
radiation, acceptance to patients, and cost. Often new imaging modalities 1678 
and or approaches are introduced into clinical practice with limited data. 1679 
The cost of conducting large comparative studies and the rapid advances 1680 
in the underlying technology, that may occur during the conduct of a study, 1681 
may impact negatively on decisions to conduct such comparative studies. 1682 
However, there is a pressing need to perform such technology appraisals. 1683 
An important area is the diagnosis of CTEPH, where there have been 1684 
significant advances in the imaging of the pulmonary vasculature. 1685 
Additional data is required to critically evaluate these new techniques and 1686 
challenge current guideline approaches. Importantly a number of studies 1687 
are planned, including the prospective, multicentre, comparative phase III 1688 
diagnostic trial CHANGE-MRI, a European multi-centre study comparing 1689 
functional MRI and VQ-SPECT. This study aims to recruit 1000 patients 1690 
(clinicaltrials.org).  The INSPIRE study is a pilot non-inferiority study 1691 
comparing iodine subtraction mapping with VQ-SPECT in patients with 1692 
suspected CTEPH (clinicaltrials.gov). A prospective study comparing the 1693 
cost and utility of follow-up approaches using  echocardiography and 1694 
cardiac MRI in patients with PAH is highly desirable. 1695 
 1696 
An additional important area of research is the optimisation of initial 1697 
diagnostic testing and follow-up based on imaging availability, particularly 1698 
where imaging and invasive testing are limited  1699 
 1700 
6.3 Combining imaging with other modalities (Genetics and MRI 1701 
augmented right heart catheterisation) 1702 
With advances in genetics and imaging there is an opportunity to better 1703 
understand genotype phenotype associations that have the potential to aid 1704 
clinical decision making. Heterozygous mutations in the gene encoding 1705 
bone morphogentic protein receptor type 2 (BMPR2) are the most 1706 
common genetic cause of pulmonary arterial hypertension, occurring in 1707 
~15% of cases [185]  and have been associated with worse right 1708 
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ventricular function on cardiac MRI [305].  Bi-allelic mutations in the 1709 
eukaryotic translation initiation factor 2 alpha 5 kinase 4 gene (EIF2AK4) 1710 
are described in pulmonary veno-occlusive disease and pulmonary 1711 
capillary haemangiomatosis [306, 307], which are important to diagnose 1712 
given their worse prognosis and poorer response to PAH therapies.  In a 1713 
large international cohort study [185], patients with PVOD were diagnosed 1714 
based on radiological criteria, however, a number of patients who were 1715 
carriers of EIF2AK4 were not identified by imaging alone. These patients 1716 
were younger and had a lower gas transfer factor and greater interlobular 1717 
septal thickening and mediastinal lymphadenopathy. This suggests that 1718 
combining imaging with genetic testing in at risk patients has the potential 1719 
to improve diagnostics and prognostication.  Integration of genetics, 1720 
clinical data and imaging is an exciting area for further research. 1721 
Diagnosis and accurate prognostication in patients with pulmonary 1722 
vascular disease remains challenging. Haemodynamic data from right 1723 
heart catheterisation provides important information with direct pressure 1724 
measurement. However, it does not provide a complete morphological or 1725 
functional assessment of the right ventricle and pulmonary circulation.  1726 
MRI augmented catheterization involves invasive right heart 1727 
catheterization performed inside the MRI system [276, 308, 309]. It 1728 
combines simultaneous invasive hemodynamic and MRI morphological 1729 
and functional assessment in a single radiation-free procedure, providing 1730 
detailed physiological insights. Further work to investigate the potential 1731 
advantages in terms of clinical utility, improved understanding of disease, 1732 
patient acceptability and cost is recommended. 1733 
 1734 
6.4 Improving our understanding of pulmonary vascular disease by 1735 
assessing the distal vasculature and using novel imaging 1736 
approaches 1737 
A limitation of current imaging modalities in pulmonary hypertension is the 1738 
insensitivity to visualise and interrogate the distal pulmonary arterial 1739 
vasculature, the primary site of disease in patients with PAH. Assessing 1740 
pulmonary perfusion directly using novel MR or CT methods may provide 1741 
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a significant insight to the underlying small vessel vasculopathy. Temporal 1742 
and spatial heterogeneity of the blood flow in patients at baseline and 1743 
during PAH therapy is an area for further research.  1744 
 1745 
Inhaled Xe129 hyperpolarised gas imaging is an emerging technique. 1746 
Reports of hyperpolarised gases in CTEPH have suggested a potential 1747 
role in follow-up of patients [310] and abnormalities in idiopathic PAH have 1748 
also been reported [311].  A patient inhales Xe129 gas and ventilation 1749 
images are acquired. Xe129 possesses relatively high solubility in tissues 1750 
and blood. The transit of the gas from gas to dissolved phase can be 1751 
probed using MRI spectroscopy. This allows the acquisition of functional 1752 
parameters characterizing the gas exchange as well as  gas uptake by 1753 
imaging the dissolved-phase. By studying these Xe129 diffusion properties, 1754 
various microstructure parameters including alveolar-volume ratio, blood-1755 
gas barrier thickness, and surface-to-volume ratio can be determined.  1756 
 1757 
6.5 Stress imaging of the cardiopulmonary system  1758 
Imaging in patients with suspected pulmonary hypertension is usually 1759 
undertaken at rest but there is increasing interest in evaluating changes in 1760 
pulmonary artery pressure and right ventricular function on exercise and 1761 
following other acute interventions.  Exercise echocardiography is well 1762 
described [312-315] in the assessment of patients with pulmonary 1763 
hypertension, but currently its use is not widespread.  There is increasing 1764 
interest in using cardiac MRI and augmented MRI right heart 1765 
catheterisation to assess cardiopulmonary system on exercise to 1766 
determine the differential response of RV morphology and function in 1767 
health and disease. Further evaluation of the effect of acute interventions 1768 
such as fluid and acute vasodilator challenges would also be of value. 1769 
 1770 
6.6 Artificial intelligence (AI) and applications in pulmonary 1771 
hypertension 1772 
With the rapid development in machine learning technologies, there is 1773 
huge potential to improve imaging assessments. Image acquisition, 1774 
analysis and interpretation are areas that may benefit from integration of 1775 
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AI technologies. There are a number of recent publications in this area 1776 
[293, 296, 297]. Notable areas for further research include acceleration of 1777 
MRI acquisition, improved segmentation of the cardiac chambers on CT 1778 
and MRI and the pulmonary vasculature on CT and diagnostic and 1779 
prognostic classification and interpretation. 1780 
 1781 
6.7 The impact of imaging on patients and users 1782 
Much of the focus of imaging research is based on the knowledge that can 1783 
obtained by the images themselves. However, an important area of 1784 
investigation is the impact of imaging; on patients and their families, 1785 
physicians and healthcare professionals, researchers who interpret the 1786 
images and health care systems that fund imaging. The acceptability, 1787 
emotional impact and cost of clinical pathways to diagnose and serially 1788 
assess patients requires further research, including the relative tolerability, 1789 
risks and benefits of different imaging approaches. A study evaluated the 1790 
social and technological epistemology of clinical decision making as 1791 
mediated by imaging [316]. This study illustrated that images can fulfil a 1792 
mediating role by aiding acquisition of knowledge and facilitating 1793 
communication in addition to illustrating the highly social aspects of 1794 
interactions with patients and within multidisciplinary meetings. 1795 
Involvement of patients and their families and users of imaging is required 1796 
if imaging is going to fulfil its potential. 1797 
 1798 
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Tables 1819 
 1820 
Table 1 Recommended imaging investigations in adults with 1821 
pulmonary hypertension considered for specific pulmonary vascular 1822 
interventions 1823 
 1824 
 Imaging investigations 
 
All patients 
Echocardiography 
CTPA or DECTA or CT-LSIM 
Perfusion lung imaging in selected patients (see section 3.2)  
Liver disease 
suspected or 
known 
 
Ultrasound scan of liver with portal Doppler 
Congenital heart 
disease suspected 
or known 
Consider: 
CMRI with Qp:Qs   
Transoesophageal echocardiogram 
Left heart disease 
or respiratory 
disease 
CMRI or further echocardiographic studies to assess right ventricular 
function may reduce the need to proceed to cardiac catheterisation 
 
Suspected CTEPH 
 
Consider: MR angiography or digital subtraction angiography 
Lung ventilation 
If malignant obstruction suspected FDG-PET CT recommended 
 
Unexplained 
hypoxaemia 
 
Consider:    Bubble Echocardiography  
Renal Q SPECT 
CMRI Qp:Qs  
MR time resolved imaging 
Follow-up of right 
ventricular 
function 
Echocardiography 
CMRI 
 1825 
CTPA=CT pulmonary angiography, DECTA=Dual energy computed tomography angiography, CT-1826 
LSIM=computed tomography lung subtraction iodine mapping, CMRI, cardiac magnetic resonance 1827 
imaging, Qp:Qs= Pulmonary-Systemic Flow Ratio, FDG-PET CT = fluorodeoxyglucose-positron 1828 
emission tomography computed tomography, SPECT= Single Photon Emission Computed 1829 
Tomography   1830 
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Table 2 Imaging modalities used in paediatric pulmonary 1831 
hypertension 1832 
 1833 
 
Modality 
 
 
Adaptation 
 
Problem 
 
 
Echocardiography 
Higher frequency probes 
provide better spatial and 
temporal resolution in 
children.  Optimised sector 
width and focal length 
improves image quality in 
children. 
High heart rate, 
small structures but 
better echo windows 
reduced distance 
from probe to 
structure of interest 
 
CT imaging 
 
Multislice 
Small structures, 
high heart rates, 
movement, difficulty 
in breath holding, 
need to avoid 
sedation 
anaesthesia 
 
 
MR imaging 
Rectangular field of view, 
partial Fourier encoding, 
patient friendly MR 
environment, use of novel 
real-time 
sequences/undersampling 
with novel reconstruction 
Small structures, 
high heart rates and 
respiratory rates, 
movement and 
difficulty breath 
holding, need to 
avoid anaesthesia 
 1834 
CT=computed tomography, MR=magnetic resonance 1835 
 1836 
 1837 
 1838 
 1839 
 1840 
 1841 
 1842 
 1843 
 1844 
 1845 
 1846 
 1847 
 1848 
 1849 
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 1850 
 1851 
 1852 
 1853 
 1854 
 1855 
Table 3: Echocardiographic variables used at diagnosis and follow-1856 
up in paediatric pulmonary hypertension 1857 
 1858 
 
Echo 
Variables 
 
 
Interpretati
on 
 
Advantage 
 
Limitations 
 
Referenc
es  
 
 
Interventricu
lar septal 
flattening 
Mild, 
moderate, 
or severe to 
indicate the 
severity of 
pulmonary 
hypertensio
n 
Quick visual 
assessment
s when 
there is not 
adequate 
TR peak 
velocity to 
estimate 
RVSP 
Qualitative.  
Can occur 
in systole 
and diastole 
depending 
on pressure 
or volume 
overload 
Poor 
validation 
with 
clinically 
relevant 
measures 
[317, 318] 
 
 
 
TR peak 
velocity 
(m/s) 
RVSP = 
SPAP = 
4(TR max)² 
+ mean RA 
pressure 
(mRAP).  If 
TR velocity 
is >3m/s, 
PH may be 
suspected 
Easy to 
obtain 
75% is 
measurable 
modest 
correlation 
with systolic 
pulmonary 
artery 
pressure 
[319] 
 
 
Mean PAP 
(mmHg) 
mPAP = 4 
V(early 
peak 
pulmonary 
Alignment 
of PR 
maybe 
PR required 
for 
measureme
nt 
[260, 263] 
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regurgitatio
n velocity)² 
+ RAP 
better than 
TR 
modest 
correlation 
with mean 
pulmonary 
artery 
pressure 
not 
substitute 
for cardiac 
catheterisati
on 
 
Diastolic 
PAP (mmHg) 
DPAP = 4 
V(end-
diastolic 
pulmonary 
regurgitatio
n velocity)² 
+ RAP 
 
Alignment 
of PR 
maybe 
better than 
TR 
PR required 
for 
measureme
nt 
[260, 263] 
 
 
 
TAPSE (mm) 
Longitudinal 
systolic 
function 
Easy to 
obtain, 
impaired RV 
systolic 
function 
when the 
TAPSE is < 
than 2 
standard 
deviation of 
age related 
value 
Single 
dimension, 
does not 
take into 
account of 
the 
circumferen
tial or radial 
function of 
the RV.  
Alignment 
can be a 
problem 
Poor 
correlation 
with RV 
function and 
survival 
 
[320, 321] 
 
 
PAAT (ms) 
Abnormal 
PAAT 
values with 
z-score < -2 
Can easily 
be 
measured in 
all patients 
HR 
dependent 
[256, 322] 
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SD were 
predictive of 
PH. 
 
RV TDI E’ 
(cm/s) 
< 8cm/s 
may 
indicate 
increased 
risk of 
mortality 
Can easily 
be 
measured in 
all patients 
HR 
dependent 
[323] 
 
 
RV TDI MPI 
Abnormal 
TDI MPI 
values 
indicates 
right 
ventricular 
dysfunction 
Can easily 
be 
measured in 
patients 
HR 
dependent 
[324] 
 
S/D ratio 
>1.4 
indicates 
severity of 
PH and 
increased 
risk of 
mortality 
Can easily 
be 
measured 
from TR 
velocity 
Presence of 
defined TR 
velocity in 
systole and 
diastole 
[272] 
 
 
End-systolic 
RV/LV ratio 
>1 may 
indicate 
increased 
risk of 
adverse 
events in 
pediatric 
pulmonary 
hypertensio
n 
Easy to 
obtain 
clinically 
Cannot be 
used in 
patients 
with left to 
right shunts. 
[325] 
 
 
RV FAC (%) 
Decreased 
FAC 
(<35%) 
correlates 
with 
decreased 
Clinically 
easy to 
obtain 
Does not 
take into 
account of 
the entire 
right 
ventricle 
[324] 
DOI: 10.1177_2045894019841990 
 
 66 
systolic 
function 
 
 
 
 
3D RV EF 
(%) 
Decreased 
RV EF 
(<45%) 
indicates 
decreased 
RV function 
Full volume 
datasets to 
evaluate for 
right 
ventricular 
volumes 
and 
function.  
Accurate 
measureme
nts of right 
ventricular 
function and 
can be 
prognostic 
in 
pulmonary 
hypertensio
n 
Required 
breath 
holding for 
adequate 
volumes.  
Can be 
difficult 
even in 
single beat 
acquistions 
when the 
pediatric 
probe is too 
big. 
[268, 326] 
 
 
 
 
RV strain 
(%) 
RV free wall 
longitudinal 
strain 
decrease 
indicates 
decreased 
systolic RV 
function. 
RV free wall 
longitudinal 
strain 
maybe 
more 
sensitive in 
detecting 
ventricular 
function and 
is 
prognostic 
in 
pulmonary 
hypertensio
n 
May not  
have 
adequate 
frame rate 
when the 
heart rate is 
too high.  
[273] 
 
 
 
LV EF (%) 
LV EF may 
be 
decreased 
in severe 
Quantificati
on of LV 
function 
Bi-plane 
Simpson’s 
may not be 
accurate as 
[324] 
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pulmonary 
hypertensio
n via RV-LV 
interaction 
the LV is 
distorted in 
severe PH, 
 1859 
TR=tricuspid regurgitant, RVSP=right ventricle systolic pressure, SPAP=systolic 1860 
pulmonary arterial pressure, V=velocity, RA=right atrium, PH=pulmonary hypertension, 1861 
RAP=right atrial pressure, DPAP=diastolic pulmonary arterial pressure, PAAT=pulmonary 1862 
arterial acceleration time, SD=standard deviation, TDI=tissue Doppler imaging, 1863 
MPI=Myocardial performance index, FAC=fractional area change, RV EF=right ventricle 1864 
ejection fraction, LV EF=left ventricular ejection fraction 1865 
 1866 
 1867 
 1868 
Table 4: Echocardiographic views to obtain functional parameters in 1869 
paediatric pulmonary hypertension 1870 
 1871 
 View Functional Parameters 
Anatomy Parasternal 
short axis 
End-systolic RV/LV ratio [325] 
 
 
 
Doppler 
Parasternal 
short axis 
Pulmonary acceleration time/ejection time 
Pulmonary regurgitation early and late diastolic 
velocity 
 
 
Apical 4-
chamber 
Tricuspid regurgitation severity (none, mild, 
moderate, severe) 
Tricuspid regurgitation peak velocity 
Myocardial performance index (tricuspid tissue 
Doppler) [327] 
Systolic/diastolic (S/D) duration ratio from TR 
Doppler[272]  
Tissue Doppler systolic and diastolic velocities 
(tricuspid, septal, mitral) 
Right 
atrium 
Apical 4-
chamber 
Right atrial area (RA) 
 
 
 
Right 
ventricle 
 
 
 
Apical 4-
chamber 
Qualitative RV function (good, 
mildly/moderately/severely depressed) 
RV end diastolic and end-systolic dimensions 
indexed for BSA (2D) 
Fractional area of change (FAC) % 
Tricuspid Annular Planar Systolic Excursion 
(TAPSE) with z-score (M-mode when available, 2D) 
RV strain (global and segmental) [43, 326, 328] 
3D RV volumes and function [268, 326] 
 
Left 
ventricle 
Apical 2+4 
chamber 
LV ejection fraction (bi-plane Simpson or 5/6 area-
length method)  
LV eccentricity index[317]  
LV strain (global) [329]   
3D LV volumes and function [324] 
Other  Presence and severity of pericardial effusion (none, 
small, moderate, large)[231] 
RV=right ventricle, LV=left ventricle, TR=tricuspid regurgitant jet BSA=body surface area, 1872 
 1873 
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Figures 1875 
 1876 
Figure 1 PVRI diagnostic algorithm 1877 
Figure Legend: Please see section 3.2 pages 38-44 for detailed 1878 
description of how to navigate the algorithm.  1879 
 1880 
 1881 
Abbreviations: PH: pulmonary hypertension, PAH: pulmonary arterial 1882 
hypertension, CTEPH: chronic thromboembolic pulmonary hypertension, 1883 
ECG: electrocardiogram, DLco: diffusing capacity of the lungs for carbon 1884 
monoxide, CXR: chest radiograph, CMRI: cardiac magnetic resonance 1885 
imaging, CTPA computed tomography pulmonary angiography, DECTA: 1886 
dual energy computed tomography angiography, CT-LISM: computed 1887 
tomography lung iodine subtraction mapping, SPECT: single photon 1888 
emission computed tomography, RV right ventricular. In this algorithm 1889 
patients are classified into low, intermediate and high risk of pulmonary 1890 
hypertension according to ESC/ERS guidelines [2]. 1891  1892 1893 
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